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                                                                Abstract 
 
       Stress is known to exert an influence on neuroendocrine, autonomic, hormonal, and  
 
immune functioning.  As a result of the debilitating effects of stress on numerous bodily  
 
systems, there exists a large body of research devoted to the etiology, physiological 
 
sequelae, and treatment of the condition.  Further, the neurotransmitter serotonin (5-HT)  
 
has been implicated in stress responding.  Presently, there is conflict in the literature as to  
 
the precise role serotonin plays in mediating the stress response.  This study was an  
 
attempt to further elucidate the role of 5-HT in mediating an organism’s response to tail  
 
pinch stress and the open field.  Previously, we have demonstrated that peripheral  
 
administration of the broad-spectrum 5-HT2 agonist, DOI, reduces stress responding in  
 
rats subjected to a tail pinch stressor (Hawkins, et al., 2002).  This effect was fully  
 
blocked by peripheral coadministration of the broad spectrum 5-HT2 antagonist,  
 
ketanserin.  The present study examined further the role of the 5-HT2 receptor subclass in  
 
mediating the stress response.  We employed antagonists that selectively target either the  
 
5-HT2A or 5-HT2C receptor in an effort to clarify the relative importance of each of  
 
these receptors in mediating the stress response.  These compounds were injected  
 
subcutaneously in an effort to black the effects previously seen with DOI.  DOI  
 
attenuated rearing and oral behavior directed at food, while increasing the frequency of  
 
head and body shakes in the open field.  DOI-induced head shakes were blacked by the  
 
5-HT2C antagonist, SDZ SER 082, as well as by a combination of SDZ SER 082 and the  
 
5-HT2A antagonist, spiperone.  Implications for the 5-HT2 receptor subclass in mediating  
 






                                                               Introduction 
  
       Stress can be described as an organism’s response to any influence exerted by  
 
environmental or endogenous factors that disrupt homeostatic mechanisms within the  
 
organism.  These influences, or stressors, can be physical or psychological in nature, and  
 
have wide-ranging effects on neuroendocrine, autonomic, immune, and hormonal function.   
 
In humans, stress has been linked to a broad spectrum of illnesses, including major depressive  
 
disorders, Alzheimer’s disease, general neurodegeneration, hypertension, and asthma  
 
(McEwen and Stellar, 1993). Given the well-known debilitating effects of stress, there exists  
 
a large body of literature aimed at elucidating the etiology, physiological sequelae, and  
 
treatment of the condition.       
 
General Theories of Stress 
 
       In Walter Cannon’s classic “fight-or-flight” paradigm, an organism’s sympathetic  
 
nervous system is activated in response to physical and emotional stressors.  In the case of a  
 
physical threat, the “fight or flight” reaction is a near-instantaneous sympathetic response that  
 
allows an organism to engage, or escape from a perceived environmental threat, such as a  
 
natural predator.  Cannon noted that milder emotional states such as joy, grief, or disgust  
 
were capable of prompting sympathetic arousal as well (Cannon, 1929).  Despite categorical  
 
distinctions, physical and emotional stressors were thought to prompt similar, if not equal  
 
activation of the sympathetic nervous system.  Additionally, Cannon coined the term  
 
homeostasis in reference to an organism’s ability to maintain internal constancy in the face of  
 
great changes in the surrounding environment.   
 
        Building upon the work of Cannon, Austrian physician-endocrinologist Hans Selye  
 






stress.  Observing several common features of “sickness” in patients diagnosed with a  
 
wide range of illnesses, Selye developed a model termed the General Adaptation  
 
Syndrome (GAS), which outlined the physiological processes associated with the stress  
 
response (Selye, 1956).  The GAS offered no theoretical distinctions between the body’s  
 
response to emotional or physiological factors, be they positive or negative.  Selye argued  
 
that the body responded in a nonspecific manner, via the GAS, to an essentially infinite  
 
amount of specific stressors (Selye, 1956).  Perhaps most notably, Selye theorized that  
 
neuroendocrine responses to stress were intrinsically related to immune functioning.  As  
 
such, many ailments resulted not from a specific influence, such as intoxication or  
 
infection, but from the inability of an organism to respond appropriately to the stressor  
 
through activation of the GAS.  Thus, when an organism failed to meet the demands  
 
placed upon it by stress, certain physiological manifestations such as ulceration and  
 
hypertension would surface.   
 
        The theories of Cannon and Selye provide groundwork for understanding the   
 
physiological responses associated with stress, particularly with regard to nonspecific  
 
sympathetic arousal, which will be discussed later.  In contrast, the recent work of James  
 
Deakin and Frederico Graeff has culminated in a theoretical model that distinguishes  
 
between various types of stressors, while proposing distinct neural mechanisms  
 
associated with each of them (Graeff, Guimares, Andrades, and Deakin, 1996).  This  
 
particular theory hinges largely on an organism’s response to proximal and distal threats  
 
(Graeff, et al., 1996).  Potential (distal) threats are theorized to activate neural substrates  
 
that mediate anticipatory anxiety in situations where an organism must evaluate a  
 






that generates intense panic in response to immediate threats such as physical pain,  
 
asphyxia, or impending attack by a predator (Graeff, et al., 1996). Although distinct  
 
serotonergic pathways are hypothesized to play a role in the response to each class of  
 
stressor, each mechanism plays a common role in activating sympathetic arousal,  
 
vigorous escape behavior, and analgesia (Graeff, 1993).       
 
Physiological Effects of Stress 
 
        Sympathetic Nervous System.  It is difficult to discuss stress responding without  
 
devoting significant attention to the sympathetic nervous system.  Activation of the  
 
sympathetic nervous system is known to effect powerful short-term changes in the body,  
 
largely through the release of catecholamines.   Epinephrine and norepinephrine are most  
 
commonly associated with this process which is thought to promote beneficial behavior in  
 
situations of “fight or flight” (Udelsman and Holbrook, 1994).  A cursory review of the  
 
sympathetic effects on an organism reveals the utility of this system in the activation of  
 
vigorous behavior.  Among the changes induced by this response are increases in arterial  
 
blood pressure, increased blood flow to active muscles, decreased blood flow to organs  
 
not aiding intense motor activity, increased cellular metabolism, increased glycolysis in  
 
muscles and the liver, as well as increased muscle tone (Guyton and Hall, 1996).  The  
 
specific role of the catecholamines in mediating the stress response will be discussed later.     
 
        The Hypothalamic-Pituitary-Adrenal Axis. The HPA axis is a set of structures in the  
 
brain and peripheral nervous system regarded as an integral mediator of the stress  
 
response.  Acting in concert with the sympathetic nervous system, the primary function of  
 
the HPA axis is to facilitate the rapid release of glucocorticoid hormones into the  
 






1996).  Much like the effects of catecholamines, glucocorticoids allow vigorous  
 
activity by promoting glucose release in the liver, increased cardiovascular activity, and  
 
deactivation of nonessential endocrine systems (Munck, Guyre, and Holbrook, 1984).  In  
 
essence, the HPA axis primes the body for adaptive behavior that benefits short-term  
 
survival in situations that are acutely stressful or threatening.  Additionally, the HPA axis  
 
seems to function in the long-term as a physiological coping mechanism, a role mediated  
 
by a feedback loop that will be described in greater detail later.   
 
        Stressors initiate stress responding at the level of the hypothalamus, the first  
 
component in the triad of structures that comprise the HPA axis.  Here, corticotropin- 
 
releasing factor (CRF) is released from neurons originating in the paraventricular nuclei   
 
(Makara, Stark, Karteszi, Palkovits, and Rappay, 1981).  CRF is then transported through  
 
the hypophyseal portal system, arriving at the anterior pituitary gland, where it stimulates  
 
the production of adrenocorticotropin, or ACTH (Hodges, 1984).  ACTH is then secreted  
 
into the bloodstream, eventually arriving at the adrenal cortex where it stimulates 
 
increases in cyclic adenosine monophosphate (cAMP) levels and production of the  
 
glucocorticoid cortisol (corticosterone in rats) (Honn and Chavin, 1977).  At this level of  
 
the HPA axis, cortisol is secreted into the bloodstream from the adrenal cortex.  
 
        Cortisol serves multiple functions in the central and peripheral nervous systems.   
 
Noted mainly for its anti-inflammatory properties, cortisol is also a powerful  
 
immunodepressant.  Additionally, cortisol plays a role in maintaining water and  
 
electrolyte concentrations, gastric secretions, as well as promoting lipid, carbohydrate and  
 
protein metabolism (Simmons, Miles, Gerich, and Haymond, 1984).  Cortisol also  
 






as well as tissue repair in injured organisms, clearly adaptive effects with respect to  
 
physical stress (Udelsman and Holbrook, 1994; Kudsk and Mirtallo, 1983).   
 
        Negative Feedback in the HPA Axis.  Chronically elevated glucocorticoid levels have  
 
been shown to adversely affect metabolic processes, disrupt the immune response, and  
 
play a role in the etiology of depression and other neurobiological disorders (Rebuffe- 
 
Scrive, Walsh, McEwen, and Rodin, 1992; Dhabhar and McEwen, 1997; Mizoguchi,  
 
Yuzurihara, Ishige, Sasaki, Chui, and Tabira, 2001).  Thus, there is an apparent need for a  
 
regulatory mechanism that terminates stress responding, as continued elevation of  
 
glucocorticoid levels is maladaptive (McEwen, De Kloet, and Rostene, 1986).  Cortisol  
 
plays an important role in regulating basal and stress-evoked levels of ACTH through the  
 
initiation of a negative feedback loop involving the hypothalamus, pituitary,  
 
hippocampus, amygdala, septum and other midbrain structures (McEwen, et al., 1986).   
 
Corticosteroids have been shown to have a direct inhibitory effect at the level of the  
 
hypothalamus and pituitary, resulting in decreased secretion of CRF and ACTH,  
 
respectively (Jacobson and Sapolsky, 1991).  Other brain structures, most notably the  
 
hippocampus and frontal cortex have been shown to inhibit HPA axis activity by  
 
decreasing CRF and vasopressin secretion (Jacobson and Sapolsky, 1991).  Conversely,  
 
certain nuclear groups of the amygdala have been shown to activate the HPA axis by  
 
stimulating increases in ACTH and cortisol release (Van de Kar & Blair, 1999).   
         
Monoaminergic Regulation of Stress 
 
The monoamines are found throughout central and peripheral tissues and are subdivided into 
 
two classes: the catecholamines and the indolamines.  Both groups exert varying degrees of  
 






       Catecholamines: A Brief Overview.  Norepinephrine and epinephrine, the  
 
catecholamines most relevant to the study of stress responding, are secreted peripherally  
 
by postganglionic sympathetic nerves and the adrenal medullae.  In the central nervous  
 
system, the bulk of norepinephrine is produced in the locus coeruleus, although various  
 
nuclear groups of the hypothalamus, amygdala, and other groups synthesize the  
 
neurotransmitter as well (Pacak, Palkovits, Kopin, and Goldstein, 1995).  Dopamine, a  
 
third catecholamine that plays a role in stress responding, is manufactured in  
 
the brain primarily by the substantia nigra and surrounding nuclear groups.           
 
        Catecholamines and Stress.  Generally, the catecholamines are thought to stimulate  
 
activity in the HPA axis (Herman, et al., 1996).  Exposure to a variety of physical and  
 
psychological stressors has been shown to elevate levels of norepinephrine in the  
 
hypothalamus, amygdala, and other brain structures intrinsically related to activation of  
 
the HPA axis (Pacak, et al., 1995).   Introcerebroventricular (ICV) injections of  
 
norepinephrine and epinephrine have been shown to increase plasma ACTH levels and  
 
induce an increase in hypophyseal portal levels of CRF (Szafarczyk, Malaval, Laurent,  
 
Gibaud, and Assenmacher, 1987; Plotsky, 1987).   
 
        Lesion and stimulation studies have been integral to our understanding of  
 
catecholaminergic systems in the HPA axis, as well.  Chemical lesion of the ventral  
 
noradrenergic bundle, a major adrenergic pathway innervating the hypothalamus, results  
 
in a drastic decrease in blood levels of CRF as measured in the hypophyseal portal  
 
system, as well as decreased hypothalamic levels of norepinephrine and epinephrine  
 
(Guillaume, et al., 1987).  Stimulation of the same nerve bundle has been shown to  
 






suggest a stimulatory role of the catecholamines in HPA axis functioning (Cunningham  
 
and Sawchenko, 1988; Cunningham, Bohn, and Sawchenko, 1990).   
    
Serotonin and Stress 
 
       Since its discovery in the 1930s, serotonin (5-HT, 5-Hydroxytryptamine; see Figure 1)  
 
has become the focus of intense research in diverse fields including biochemistry, psychology,  
 






Figure 1: Serotonin 
 
serotonin was later isolated in platelets, functioning as a vasoconstrictor upon its release into  
 
clotting blood (Erspamer, 1966; Rapport et al., 1948).  Additionally, it was discovered that  
 
patients suffering from intestinal enterochromaffin tumor excreted relatively large  
 
volumes of the serotonin metabolite 5-hydroxyindoleactic acid in urine, a prominent marker  
 
that is still used in screening for gastrointestinal cancer today (Wilander, Lundqvist, and  
 
Oberg, 1989).  This excess secretion of 5-HT, termed carcinoid syndrome, produced  
 
cutaneous flushing, diarrhea, bronchospasm, and right-sided valvular lesions, as well as  
 
psychotic effects similar to those produced by lysergic acid diethylamide (LSD).  This  
 
behavioral link to LSD was one of the first pieces of data suggesting a presence of 5-HT in  
 









functions as a neurotransmitter, and in some cases, a neuromodulator, eliciting a wide range  
 
of acute and generalized actions in multiple bodily systems. 
 
Serotonin Receptor Subtypes 
 
        In evolutionary terms, serotonin is one of the oldest biologically active substances,  
 
perhaps even predating the existence of adrenergic and cholinergic neurotransmitters  
 
(Venter, et al., 1988).  In addition to humans and other mammals 5-HT is also present in  
 
mollusks, arthropods, insects, as well as some fruits and nuts (Feldman and Lee, 1985;  
 
Tarchalska-Krynska and Kostowski, 1976).  Interestingly, the structural features of the  
 
serotonin molecule have been conserved over millions of years, while 5-HT receptors  
 
themselves have evolved into pharmacologically distinct networks (Venter, et al., 1988). 
 
        Today, a concise system of categorizing 5-HT receptor subtypes has been developed.   
 
There are currently seven families of 5-HT receptors, numbered 5-HT1-7.  Further  
 
subdivisions exist within these families (e.g., 5-HT1A,1B,1C)  Of the families mentioned  
 
above, 5-HT1, 5-HT2, and 5-HT3 receptors have been researched in greatest depth, and  
 
will be discussed in relation to their relevance to the study of stress and anxiety.   
                
        The 5-HT1 Receptor Subtype: An Overview.   5-HT1 receptors are found throughout  
 
the central and peripheral nervous system, where they share a common role in decreasing  
 
serotonergic activity (Marcinkiewicz, Verge, Gozlan, Pichat, and Hamon, 1984; Radja,  
 
Laporte, Daval, Verge, Gozlan, and Hamon, 1991; Hoyer, et al., 1994).  The 5-HT1A, 1B,  
 
and 1D receptors have been studied in greatest detail, and appear to function both 
 
presynaptically and postsynaptically.  In the former case, 5-HT1 receptors serve as  
 
autoreceptors, reducing synthesis and firing rates of 5-HT neurons (de Montigny and  
 






receptors are found in various forebrain sites, especially the hippocampus, where they are  
 
thought to have a hyperpolarizing effect, thereby reducing the effects of 5-HT in the  
 
synapse.  The 5-HT1C receptor subclass has been found to share sufficient features with  
 
the 5-HT2 family that it has been renamed 2C, accordingly (Humphrey, Hartig, and Hoyer,  
 
1993).  Little is known about the 5-HT1E and 1F families, though they share many of the  
 
primary features of the 5-HT1 family.  Development of specialized ligands for these  
 
receptors will facillitate subsequent pharmacological categorization. 
 
        Clinical Significance of the 5-HT1 Receptor Family.  Selective and/or partial  
 
agonists of the 5-HT1A receptor have proven efficacious in the treatment of depression  
 
and anxiety, suggesting that both disorders have a common root involving serotonergic  
 
function (Deakin, 1998).  Buspirone (Buspar), the first clinically available drug of this  
 
nature, is a selective partial agonist at the 5-HT1A receptor that has garnered attention as  
 
a non-sedative anxiolytic, effective in the treatment of generalized anxiety disorder 
 
(Gammans, Stringfellow, Hvizdos, Seidehammel, Cohn, Wilcox, et al., 1992).  Notably,  
 
the anxiolytic and antidepressant effects of buspirone and other 5-HT1A agonists are  
 
generally only observed after one to three weeks of chronic administration.  Such findings  
 
suggest that a secondary mechanism, such as presynaptic autoreceptor downregulation  
 
may be responsible for the therapeutic benefit seen after treatment with 5-HT1A agonists.     
 
         Behavioral Effects of 5-HT1 Receptor Ligands.  Animal studies utilizing 5-HT1  
 
ligands have produced findings that vary across experimental models.  As mentioned  
 
earlier, the delayed therapeutic effect of buspirone in humans seems to suggest that an  
 
increase in 5-HT activity secondary to downregulation of presynaptic 5-HT1 receptors is  
 






injections of the 5-HT1A agonist 8-OH-DPAT have been shown to attenuate stress  
 
responding in the elevated T-maze, various restraint paradigms and the elevated plus maze  
 
(Graeff, et al., 1996; McBlane and Handley, 1994; Kennett, Dourish, and Curzon, 1987).   
 
Similarly, acute systemic administration of the 5-HT1A agonist buspirone has been shown  
 
to reduce ultrasonic vocalization, while releasing suppressed locomotor activity in  
 
response to foot shock in rats, both anxiolytic effects (Rowan, Cullen, and Moulton,  
 
1990).  Upon initial examination, these findings seem compatible with findings that 5-HT1  
 
agonists are anxiolytic in humans.  However, the delayed therapeutic effects seen in  
 
humans suggest that a different mechanism, such as presynaptic autoreceptor  
 
downregulation or postsynaptic upregulation, may be at work. 
 
        5-HT1 Receptors and Open-field Behavior.  The open field is an experimental  
 
environment that assesses animal behavior on a range of variables that include  
 
locomotion, rearing, grooming, and body posture.  Increases in locomotion and rearing  
 
are classified as exploratory behavior and are commonly associated with anxiolysis.   
 
Increases in grooming, or the presence of a creeping gait and elongated crawling posture  
 
near the periphery of the field are regarded as anxiogenic behaviors.  Head and body  
 
shakes are also observed in the open field, but are typically regarded as artifacts of drug  
 
administration rather than an indicator of a specific anxiolytic or anxiogenic effect.   
        
       The administration of a 5-HT1A agonist in rats has consistently been shown to alter   
 
locomotion in the open field.  Subcutaneous administration of the 5-HT1A agonists 8-OH- 
 
DPAT, ipsapirone, and buspirone all reduced locomotion and rearing in the open-field,  
 
both anxiogenic effects (Frances, Khidichian, and Monier, 1990, Kennett, et al., 1987).   
 






instances of rearing, while increasing movement along the periphery of the open field,  
 
effects deemed by the authors to be anxiogenic (Ahlenious, Larsson, and Wijkstrom,  
 
1991).  Though these studies suggest that administration of a 5-HT1A agonist results in  
 
increased anxiety in the open field, contrary findings have been reported.  Intra- 
 
hippocampal injections of the 5-HT1A agonist buspirone have been shown to increase  
 
exploratory behavior in the open field, as well as the elevated plus-maze (Kostowski,  
 
Plaznik, and Stefanski, 1989).   
 
        5-HT1A Receptors and the HPA Axis.  There is limited evidence to support an  
 
interaction between HPA axis functioning and the 5-HT1A receptor.  In low doses,  
 
microinjections of the 5-HT1 agonist 8OH-DPAT into the PVN or third ventricles  
 
resulted in decreased plasma levels of corticosterone, whereas high doses produced the  
 
opposite effect (Welch, Farrar, Dunn, and Saphier, 1993).  The latter finding has been  
 
replicated, with 5-HT1 agonists consistently reported to increase CRF release  
 
from the hypothalamus, followed by rises in serum levels of ACTH and corticosterone  
 
(Feldman, Newman, Weidenfeld, 2000; Hemrick-Luecke and Evans, 2002).     
 
        Genetic Alteration of the 5-HT1A Receptor.  Recent genetic manipulation of the 5- 
 
HT1 receptor level has provided compelling evidence for a role of 5-HT1A receptors in  
 
stress and anxiety.  Three strains of knockout (KO) rats, altered to lack the 5-HT1A  
 
receptor, have been shown to display increased anxiety in the open field, foot shock test,  
 
and a range of behavioral conflict paradigms (Gross, Santarelli, Brunner, Zhuang, and  
 
Hen, 2000).  It should be noted, however, that differences in stress responding in 5-HT1A  
 
KO rats seem to depend on the intensity of the stressor in certain strains of animals  
 






HT1A KO rats do not exhibit higher baseline anxiety, but display enhanced responses to  
 
stressful stimuli, such as cage changes and induced hyperthermia (Olivier, et al., 2001).   
 
        The 5-HT2 Receptor Subtype: An Overview.  The 5-HT2 receptor subclass is  
 
regarded traditionally as a mediator of certain peripheral actions of 5-HT, which  
 
include bronchoconstriction, platelet aggregation, and muscle contraction (Hoyer, et al.,  
 
1994).  Centrally, 5-HT2 receptors are likely involved in the mediation of anxiety,  
 
depression, and schizophrenia.  Currently, three subtypes of 5-HT2 receptors are  
 
recognized (2A, 2B, and 2C) 
 
        Clinical Significance of the 5-HT2 Receptor Family.  Several ligands of the  
 
5-HT2 receptor have proven effective in the treatment of clinical disorders such as  
 
depression and schizophrenia.  The 5-HT2A receptor may play a role in the etiology of  
 
schizophrenia, based on the success of the antipsychotic drug clozapine, a potent 5-HT2A  
 
antagonist (Huttunen, 1995).  Clozapine, also a dopamine D2 receptor antagonist, was an  
 
integral factor in the development of the serotonin-dopamine antagonist model  
 
of treatment for schizophrenia.  This model called for the use of single compounds that  
 
were both selective antagonists at the 5-HT2A receptor, as well as less potent blockers of  
 
the D2 receptor (Huttunen, 1995).  Risperidone, the first clinically available compound in  
 
this evolving class of antipsychotics, has shown promise in reducing the positive and  
 
negative symptoms of schizophrenia, without inducing the extrapyramidal symptoms  
 
characteristic of traditional anti-dopaminergics (Huttunen, 1995).   
 
        5-HT2 antagonists have also shown promise recently in the treatment of clinical  
 
depression.  Nefazadone, a 5-HT2 selective antagonist, improved depressive symptoms  
 






(SSRIs) and imiprimine, without inducing many of the adverse effects commonly seen in  
 
other classes of antidepressants (Davis, Whittington, and Bryson, 1997).  Mianserin, a  
 
5-HT2A/2C antagonist, has also proven effective in preventing sexual dysfunction  
 
associated with SSRIs when used in conjunction with the existing treatment regimen  
 
(Aizenberg, Gur, Zemishlany, Granek, Jeczmien, and Weizman, 1997).  Similarly,  
 
mianserin positively augmented the symptoms of treatment-resistant depression when used  
 




        Behavioral Effects of 5-HT2 Receptor Ligands.  5-HT2 agonists and antagonists  
 
have been tested extensively in several animal models of anxiety and stress.  The findings  
 
are frequently inconsistent, suggesting complex interactions between various brain  
 
sites and 5-HT receptor subtypes in the mediation of stress and anxiety. 
 
        There are several studies that suggest decreased serotonergic activity at the 5- 
 
HT2 receptor may be associated with decreased anxiety and stress responding.  Many of  
 
these studies involve the administration of a selective antagonist.  Intraperitoneal  
 
injections of SB242084, a selective brain-penetrating antagonist at the 5-HT2C receptor,  
 
has been shown to increase social interaction in rats (Kennett, et al., 1997).  Peripheral  
 
administration of mianserin, a non-selective 5-HT2 antagonist, and SB 206553, a selective  
 
2B/2C antagonist, increased punished responding in the Vogel drinking test and increased  
 
open-arm entries in the elevated plus-maze, both anxiolytic effects (Griebel, Perrault,  
 
Sanger, 1997).  In the rat ultrasonic vocalization test, social cohesion test, and the  
 








anxiolytic effects as well (Schreiber, Melon, and De Vry, 1998; Rademacher, Anderson,  
 
and Steinpreis, 2002).   
 
        Certain studies have found that increased serotonergic activity at the level of the 5- 
 
HT2 receptor class results in anxiolysis.  Intra-amygdala injections of the 5-HT2B agonist  
 
BW723C86 increased social interaction in rats, an effect antagonized by oral pretreatment  
 
with the 5-HT2B/2C antagonist SB 200646A (Duxon, Kennett, Lightowler, Blackburn, and  
 
Fone, 1997).  DOI, a nonselective agonist of the 5-HT2 receptor, was found to reduce tail- 
 
pinch-induced stress responding when injected subcutaneously, or by a combination of  
 
subcutaneous and intracerebroventricular administration (Hawkins, Uzelac, Baumeister,  
 
Hearn, Broussard, and Guillot, 2002).  
 
        In the open field, limited findings suggest that increased serotonergic activity at the  
 
5-HT2 receptor correlates with a decrease in anxiety.  DOI, a nonselective 5-HT2 agonist,  
 
increased exploratory behavior in the open field, an effect which was fully antagonized by  
 
the 5-HT2A/2C antagonist ritanserin (Kaur and Ahlenius, 1997).  Similarly, microinjections  
 
of nefazadone, a nonselective 5-HT2 antagonist, into the basolateral amygdala,  
 
potentiated the anxiogenic effects of inferior colliculus stimulation in the open field  
 
(Maisonnette, Villela, Carotti, and Landeira-Fernandez, 2000).     
 
        5-HT2 Receptors and the HPA Axis.  DOI, m-CPP, Ro 60-0175 and quipazine have  
 
been shown to increase serum concentrations of corticosterone in rats (Hemrick- 
 
Luecke and Evans, 2002; Raghavendra and Kulkarni, 2000;). This effect can be abolished  
 
by co-administration of the highly selective 5-HT2A antagonist M100907, but is only  
 








prominent role of the 2A receptor in activating the HPA axis (Hemrick-Luecke and Evans,  
 
2002).   
 
        Genetic alteration of the 5-HT2 receptor.   Limited studies involving genetic  
 
manipulation of 5-HT2 receptors have provided support for serotonergic involvement in  
 
stress responding, particularly with regard to the HPA axis.  A recent finding has shown  
 
that deletion of the 5-HT2C receptor leads to increased plasma concentrations of ACTH  
 
and corticosterone in rats subjected to repeated cage changes, suggesting  
 
hyperresponsiveness of the HPA axis in these animals (Chou-Green, Holscher, Dallman,  
 
and Akana, 2003).     
 
        The 5-HT3 Receptor Subtype: An Overview.  The 5-HT3 receptor is the only  
 
member of the 5-HT family that operates as a ligand-operated ion channel, directly  
 
influencing potentials via stimulation of cation-selective channels (Derkach, Suprenant,  
 
and North, 1989; Malone, Peters, and Lambert, 1991).  5-HT3 receptors are found at 
 
multiple locations within the peripheral and central nervous systems.  Locations relevant  
 
to the study of stress and anxiety will be discussed subsequently. 
 
        Clinical Significance of the 5-HT3 Receptor Family. The 5-HT3 receptor is well  
 
known for its role in the mediation of the emetic response.  A family of selective 5-HT3  
 
antagonists that includes granesitron, ondansetron, tropisetron, and dolasetron has proven  
 
highly effective in the treatment of emetic disorders.  It has been suggested that these  
 
drugs operate by central antagonism of 5-HT3 receptors in the chemoreceptor trigger-zone  
 
of the area postrema (Higgins, Kilpatrick, Bunce, Jones, and Tyers, 1989), though a  
 
peripheral mechanism mediated in the upper gastrointestinal tract through vagal afferents  
 






1990).  Recent research suggests that the 5-HT3 family of receptors is also involved in the  
 
etiology of a diverse array of clinical disorders that include anxiety, depression,  
 
psychosis, chronic pain, as well as drug and alcohol abuse (Greenshaw and Silverstone,  
 
1997).   
 
        5-HT3 Ligands and Stress.  Compounds that selectively target the 5-HT3  
 
receptor have been tested extensively in various animal models of physical and  
 
psychological stress.  Peripheral administration of selective 5-HT3 antagonists has been  
 
shown to reduce stress responding, in terms of both physiology and behavior, suggesting  
 
an anxiolytic effect as a result of reduced serotonergic activity at the 5-HT3 receptor.  In  
 
rats, intraperitoneal injection of the 5-HT3 antagonists ICS 205-930, GR 28032F, and  
 
ondansetron decreased stress-induced prolactin release, an anxiolytic effect (Jorgensen,  
 
Knigge, and Warberg, 1992, Nonaka, 1999).  Ondansetron has also been shown to  
 
increase exploratory behavior in the open field, as well as negating the anti-exploratory  
 
effects of caerulein, a decapeptide, in the elevated plus-maze (Stefanski, Palejko,  
 
Kostowski, and Plaznik, 1992; Vasar, Peuranen, Oopik, Harro, and Mannisto, 1993).   
 
        There is a growing body of evidence that 5-HT3 antagonists may exert their  
 
anxiolytic effects centrally.  Injections of the 5-HT3 antagonists tropesitron or  
 
ondansetron into the hippocampus and nucleus accumbens produced anxiolytic-like  
 
behavioral effects in the Vogel conflict test and the open field (Stefanski, Palejko,  
 
Bidzinski, Kostowski, and Plaznik, 1993).  These antagonists also suppressed stress  
 
responding induced by electroconvulsive shock (Kostowski, Plaznik, Nazar, and Jessa,  
 
1995).     






Theoretical Bases for Current Research 
 
        5-HT1, 5HT2 and perhaps 5-HT3 receptors have been implicated in stress  
 
responding.  Previously, we have demonstrated that subcutaneous injection of the 5- 
 
HT2A/2C agonist, DOI, dose-dependently reduces tail pinch-induced stress responding in  
 
rats (Hawkins, et al., 2002).  Additional unpublished data from our lab show that this  
 
effect can be reversed in a dose-dependent fashion by subcutaneous co-administration of  
 
the 5-HT2A/2C antagonist Ketanserin.  Further, we have observed that stress responding is  
 
not affected when 5-HT or DOI are injected into the cerebral ventricles, dorsal  
 
periaquaductal grey, or the amygdala.  Therefore, the anxiolytic action of DOI appears to  
 
be mediated by a peripheral mechanism despite the fact that DOI and ketanserin cross the  
 
blood-brain barrier.     
 
        Other findings support the theory that increased serotonergic activity at the 5-HT2  
 
receptor results in decreased anxiety.  Intra-amygdala microinjections of the 5-HT2B  
 
agonist BW723C86 have been shown to increase social interaction in the rat (Duxon, et  
 
al., 1997).  Similarly, intraperitoneal injections of the 5-HT2 agonists TFMPP and mCPP  
 
have been shown to impair inhibitory avoidance in the elevated T-maze, an anxiolytic  
 
effect (Mora, et al., 1997).  In the open field, DOI has been shown to increase exploratory  
 
behavior, an effect fully antagonized by the 5-HT2A/2C antagonist ritanserin (Kaur and  
 
Ahlenius, 1997).     
 
        In addition to the aforementioned pharmacological studies, genetic manipulation of  
 
the 5-HT2C receptor has provided further support for the role of this receptor as an integral  
 
mediator of negative feedback in the HPA axis (Chou-Green, et al., 2003).     
 






stress responding in the rat.  Experiments employed selective 5-HT2A and 5-HT2C  
 
antagonists in an effort to block the stress-related effects of peripherally administered DOI.   
 
Such experiments were intended to clarify the relative importance of these two receptor  
 




1.  The non-selective 5-HT2 agonist, DOI, injected subcutaneously, will decrease tail            
      
     pinch-induced stress responding in rats.   
 
2.  The effect of DOI on tail pinch-induced stress responding will be reduced by  
      
     peripheral co-administration of the selective 5-HT2A antagonist, spiperone. 
 
3.  The effect of DOI on tail pinch-induced stress responding will be reduced by       
      
     peripheral co-administration of the selective 5-HT2C antagonist, SDZ SER 082. 
 
4.  Spiperone and SDZ SER 082 will have no effect on stress responding when  
      
     administered alone. 
 
5.  Simultaneous administration of spiperone and SDZ SER 082 will result in greater  
 
     antagonism of DOI’s effects than that of either antagonist administered alone. 
      
6.  Subcutaneous injection of DOI will have an anxiolytic effect on animal behavior in the         
      
     open field.   
 
7.  The effect of DOI on open field behavior will be reduced by spiperone, SDZ SER 082,  
      
     or a combination of the two antagonists. 
   
8.  The administration of DOI, spiperone, SDZ SER 082 and combinations thereof,  
 
     will not impair general motor function, as measured by rotarod performance and  
  









        Determination of Doses.  In the case of DOI, drug was administered at doses that were 
 
based on previous work conducted in our lab.  We have seen an effect of medium and high  
 
doses (0.5 and 1.0 mg/kg) of DOI on stress responding, with no effect following low dose  
 
injections (0.1 mg/kg) (Hawkins, et al., 2002).  Doses of spiperone and SDZ SER 082 were  
 
determined based on an extensive search of the literature (see Tables 1 and 2).  Highest  
 
priority was assigned to literature relevant to the study of stress and anxiety, particularly  
 
studies that employed subcutaneous administration of spiperone or SDZ SER 082.  Studies  
 
utilizing alternate routes of systemic administration, such as interperitoneal injections, were  
 
considered, as well.  Lastly, low priority was assigned to literature unrelated to stress, but  
 
that employed relevant compounds, a systemic route of administration and behavioral  
 
dependent variables.  
 
        5-HT2A/2C Agonist.  DOI [(+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2 aminopropane;  
 







Figure 2: DOI 
 
This compound has been tested in several models of anxiety and stress mentioned  
 
previously and is known to readily cross the blood-brain-barrier (BBB).  DOI HCl was  
 







        5-HT2A Antagonist.  Spiperone (8-[3-(p-fluorobenzoyl)propyl]-1-phenyl-1,3,8- 
 
triazaspiro[4.5]decan-4-one; Figure 3; Table 1) is classified as an antipsychotic with high 
 
affinity for 5-HT2A receptors.  It is also a selective D2 antagonist and a weak antagonist of  
 











Figure 3: Spiperone 
 
       Due to the low solubility of spiperone in saline, it frequently has been administered as a  
 
suspension (e.g., Fujikawa, 1993, 1995; Kurashima, 1994, 1995; Matsumoto, 1988,  
 
1989).  The same method was employed in the current study.  Spiperone HCl was   
 
purchased from Tocris Cookson Inc. (Ellisville, MO).  
 
Table 1: References used to determine dose range for spiperone 
 
Article Author Dependant Variable Dose Range Route
Berendsen, et al., (1989) Lip retraction 0.04-0.4 mg/kg SC 
Done & Sharp, (1992) Hippocampal NE release 0.2-1.0 mg/kg SC 
Fregly & Rowland,(1988) Isoproterenol consumption 0.1 mg/kg SC 
Fujikawa, et al., (1995, 
1996) 
Yawning 0.5 mg/kg SC 
Gartside & Cowen (1990) ACTH release 1.0 mg/kg IP 
Inoue, et al., (1996) Conditioned freezing  0.1-1.0 mg/kg SC 
Kennett, et al., (1987) Restraint stress 0.1 mg/kg SC 
Kimura, et al., (1991) Yawning 0.5 mg/kg SC       
Kostrzewa & Kastin, (1993) Catalepsy 0.3 mg/kg SC 
Kurashima, et al., (1994)  Yawning, Oral Stereotopy, 
Body Temperature 
0.5 mg/kg SC 








Matsumoto, et al., (1988; 
1989) 
Yawning, prolactin secretion 0.5 mg/kg IP/SC 
Ossowska, et al., (1982) Catalepsy 0.2 mg/kg SC 
Rittenhouse, et al., (1994) ACTH secretion 0.01-0.1 mg/kg SC 
Rittenhouse, et al., (1991) Renin secretion 0.01-0.1 mg/kg SC 
Schreiber, et al., (1993) Ethanol preference 0.05 mg/kg SC 
Sobrian, et al., (2003) Grooming, oral stereotopy, 
locomotion 
0.06-1.0 mg/kg SC 
Yamada, et al., (1986) Post-decapitation convulsions 2.0 mg/kg SC 
 
       5-HT2C Antagonist.  SDZ SER 082 ((+)-cis-4,5,7a,8,9,10,11,11a-Octahydro-7H-10- 
 
methylindolo[1,7-bc][2,6]-naphthyridine; Figure 4; Table 2) is a highly selective  
 
compound at the 5-HT2B/2C receptor with a very low affinity for 5-HT1A receptors.  SDZ  
 
SER 082 has been used extensively in an effort to differentiate the behavioral effects  
 
mediated by the 5-HT2A and 5-HT2C receptors.  Notably, it has proven effective in  
 
blocking behavior induced by serotonergic agonists at the 5-HT2 receptor, in various  
 
models of stress, as well as behavioral research unrelated to stress.  SDZ SER 082  
 




Figure 4:  SDZ SER 082 
 
Table 2: References used to determine dose range for SDZ SER 082 
 
Article Author Dependent Variable Dose Range Rout
e 
Goudie, et al., (1998) Drug discrimination 
(clozapine) 









Koskinen, et al., (2000) Five-choice serial reaction 
time task 
0.1-1.0 mg/kg SC 
Krebs-Thompson, et al., 
(1998) 
Locomotor activity 0.5-1.0 mg/kg SC 
Mora, et al., (1997) Anxiety (elevated T-maze) 0.1-1.0 mg/kg SC 
Ouagazzal, et al., (2001) Prepulse inhibition 1.0 mg/kg SC 
Varty, et al., (1999) Prepulse inhibition 1.0 mg/kg SC 










































       The current study was composed of five experiments, each of which followed the same  
 
general format.  Procedures common to all of the experiments will be described collectively,  
 
followed by specific methodological alterations unique to each experiment.  
 
       All drugs were stored at room temperature in their original containers until needed.   
 
Drugs were weighed at the start of each testing day and were diluted in sterile physiological  
 
saline (0.9%) to the desired concentration.   
         
       Sixteen male Sprague-Dawley rats between the ages of 8 and 12 weeks were used for  
 
each experiment.  Animals were obtained from the Division of Laboratory Animal Medicine  
 
of Louisiana State University.  Animals were housed individually with water and laboratory  
 
chow available ad-lib.  The room in which the animals were housed were held at a constant  
 




        Each experiment employed a within-groups design, consisting of three drug conditions  
 
and a control condition in which animals received saline vehicle.  Order of presentation of  
 
experimental conditions was manipulated employing a modified Latin square design.   
 
Testing occured at three day intervals in an effort to maximize recovery time in the event  
 
that tail damage occurred during observation.    
 
Experiment One: Peripheral DOI (5-HT2A/2C Agonist) 
 
       Animals were randomly assigned to one of four experimental conditions: DOI (0.1  
 










Experiment Two: Peripheral Spiperone (5-HT2A Antagonist) 
 
        Animals were randomly assigned to one of four experimental conditions: Spiperone (0.1  
 
mg/kg, 0.5 mg/kg, and 1.0 mg/kg) and a saline control.    
    
Experiment Three: Peripheral SDZ SER 082 (5-HT2C Antagonist) 
 
        Animals were randomly assigned to one of four experimental conditions: SDZ SER 082  
 
(0.1 mg/kg, 0.5 mg/kg, and 1.0 mg/kg) and a saline control.   
 
Experiment Four: DOI + Single Antagonist 
 
        Animals were randomly assigned to one of four experimental conditions: DOI alone,  
 
DOI + Spiperone, DOI + SDZ SER 082, and a saline control.   
 
        Determination of Doses.  Doses of DOI, spiperone and SDZ SER 082 were  
 
selected based on the outcome of Experiments 1, 2 and 3.  In the case of DOI, the lowest  
 
overall effective dose in Experiment 1 was administered.  The highest dose of each  
 
antagonist was used, provided that no dose of either drug was found to significantly alter  
 
stress responding when administered alone.  If an antagonist was found to alter stress  
 
responding when administered alone, the highest ineffective dose was used in Experiment 4.   
 
Experiment Five: DOI + Multiple Antagonists. 
 
        Doses of DOI, spiperone, and SDZ SER 082 were determined based on the outcome of  
 
experiments 1, 2 and 3.  Animals were assigned to one of four experimental conditions: DOI  
 
alone, spiperone + SDZ SER 082, DOI + spiperone + SDZ SER 082, and a saline control.   
 
        Determination of Doses.  As in Experiment 4, the lowest overall effective dose of  
 
DOI was administered (based on the results of Experiment 1).  Similarly, the highest  
 










        Rater Training Criterion.  Data collectors were trained to 85% accuracy in both  
 
tail pinch and open field observations.  Animals used for training purposes were not   
 
included as subjects in subsequent experiments.  Data collectors learned to properly  
 
handle the animals, apply stressors, and record behavioral data.  Training occurred in the 
 
presence of an experienced (previously trained) rater, who also observed and recorded  
 
behavioral data.  Data collectors were required to successfully record each behavior to a  
 
degree of 85% concordance with the experienced rater in two consecutive 4-minute trials.   
 
These criteria applied to both tail pinch and open field observations. 
 
       Single Drug Injection Procedure.  Prior to receiving an injection, animals were taken  
 
from their home cages, weighed, and their tails marked for tail pinch (as described  
 
in greater detail later).  Animals were restrained by hand and received a single  
 
subcutaneous injection of drug or saline vehicle at the base of the neck.  The total volume  
 
of drug injected was based upon the individual animal’s weight and was administered in a  
 
volume of 1.0 ml per kg.  After receiving injections, animals were returned to their home  
 
cages for a period of thirty minutes.  At the conclusion of this waiting period, animals were   
 
placed in the tail pinch cage and exposed to the stressor described below.   
 
        Multiple Drug Injection Procedure.  Combination agonist/antagonist injections were  
 
administered in a volume of saline calculated based on the individual animal’s weight (1.0  
 
ml per kg).  The concentration of each drug was increased so that the total volume of  
 
injected solution was equal to that of single-injection animals.  After receiving an injection,  
 
animals were returned to their home cages for a thirty-minute waiting period, prior to  
 








        All experimental animals were observed under two conditions: the tail pinch  
 




        The Tail Pinch Stressor.  Prior to injection, animals’ tails were marked with a felt- 
 
tipped marker at a diameter of 4.3 mm.  These measurements were made using standard  
 
metal calipers.  The tails were remeasured and remarked prior to each tail pinch session  
 
to control for possible differences in diameter due to edema or growth of the animals. 
        
        The tail pinch cages were cleaned and dried before each trial.  Animals were  
 
placed in the center of the suspended wire cage, the length of the tail was guided  
 
through the cage’s floor, and a clamp was applied at the previously marked diameter.   
 
The clamp was fashioned from hemostatic forceps, padded with plastic tubing to avoid  
 
tail damage.  Animals were observed for a period of four minutes.  After observation, the  
 
forceps were removed and the animals were returned immediately to their home cages.   
 
        Dependent variables in the tail pinch.  Animals’ behavior was assessed on the  
 
following five variables during exposure to the tail pinch stressor: 
 
1. Oral behavior directed at food was defined as the total                      
 
      amount of time an animal licked, gnawed, or chewed laboratory chow.  
 
2.   Oral behavior not directed at food was defined as the  
 
      amount time an animal licked or bit the cage, or engaged in oral behavior    
 










3. Grooming was defined as the amount of time an animal engaged in  
 
licking its own body, fluffing or wiping its facial hair or whiskers with the  
 
forepaws, or directing any oral behavior toward its tail. 
 
4. Vocalizations were defined as the number of vocal emissions over the        
  
      course of the testing period. 
 
5. Fecal boli were recorded as the number of boli produced over the course of         
 
      the testing period. 
         
       After completion of the tail pinch, two measures were made of the animals’ oral  
 
behavior directed toward lab chow during the testing period: 
   
             6.   Eating was defined as the amount of lab chow an animal ingested over the  
              
                   course of the testing period.  This measure was calculated by subtracting  
               
                   the post-test weight of the lab chow from the pre-test weight. 
              
             7.   Gnawing was defined as the amount of lab chow that was shredded, but not     
                    
                   ingested by the animal over the course of the testing period.  This measure      
                    
                   was made by weighing the shredded chow that fell through the grating of the   
                   
                   cage during testing. 
 
       Open Field Testing.  Forty-five minutes after injection (roughly ten minutes after the  
 
conclusion of the tail pinch), animals were removed from their home cages and placed  
 
in the open field for observation.  The open field is an open-topped, Plexiglas box  
 
measuring 2’x2’x2’.  The floor of the apparatus is divided into four quadrants, each a 12”  
 
square.  A 75-watt light bulb is positioned directly above so that it shines down into the  
 








were observed for a period of four minutes.  Following open field testing, animals  
 
were returned to their home cages. 
         
        Dependent Variables in the Open Field.  Behavioral observation in the open field  
 
involved measurement of the following five variables: 
 
             1.   Line crosses were defined as the number of times an animal passed  
               
                   completely (all paws) into a different quadrant of the open field. 
              
             2.   Rearing was defined as any instance in which an animal lifted both front  
              
                   paws simultaneously from the floor of the open field. 
              
             3.   Head shakes were defined as any instance in which an animal vigorously  
                    
                   shook its head from side to side. 
              
             4.   Wet dog shakes were defined as any instance in which an animal shook its  
              
                   head in combination with the upper torso. 
              
             5.   Freezing was defined as the total amount of time an animal was completely  
              
                   motionless, with the exception of breathing. 
              
       Rotarod.  Twenty-four hours after the conclusion of the final day of tail pinch and  
 
open field testing, each animal was trained on the rotarod apparatus.  The rotarod  
 
consists of a textured steel drum (7.2 cm in diameter) that rotates at adjustable speeds set  
 
by the experimenter.  During training and testing, the rotarod was set to rotate at a  
 
velocity of 10 RPM.  Animals received repeated trials on the rotarod until the training  
 
criterion of thirty seconds (without falling off) was met.  Animals unable to reach the  
 
training criterion in twelve successive trials were excluded from subsequent testing.     
        
       Rotarod testing occurred twenty-four hours after training.  Animals meeting the  
 






assigned to them on the first day of stress testing.  Injections were administered as  
 
previously described and animals were returned to their home cages.  Thirty minutes  
 
later, animals were taken from their home cages and placed upon the rotarod apparatus.   
 
Animals were allowed to continue walking on the rotarod until thirty seconds passed, or  
 
the animal fell off, whichever occurred first.        
 
       Operational Definition of Anxiolytic and Anxiogenic Effects.  Anxiety was inferred  
 
when behavior occurred as a result of the imposition of a stressor upon an animal.   
 
Consistent with convention in the existing literature (e.g. Adamec, Bartoszyk, and Burton,  
 
2004; Adamec, Creamer, Bartoszyc, and Burton, 2004; Heilig, 2004; Sanchez, Gruca, Bien,  
 
and Papp, 2003; Haller and Bakos, 2002; Maslova, Bulygina, and Markel, 2002; Clark, et  
 
al., 2002; Radulovic, Ruhmann, Liepold, and Spiess, 1999), an “anxiolytic” effect was  
 
defined as a reduction in behaviors evoked by a stressor, whereas an “anxiogenic” effect was  
 
defined as an augmentation of such behaviors. 
 
       Tail Pinch.  An increase in the following behaviors was interpreted as evidence of  
 
anxiogenesis in the tail pinch condition: eating, gnawing, oral behavior directed at food, oral  
 
behavior not directed at food, grooming, vocalizations, and defecation.   
 
       Open Field.  In the open field, an increase in freezing behavior was regarded as  
 
evidence of anxiogenesis.  Increases in line crosses and rearing were considered anxiolytic  
 
effects.  The occurrence of head and body shakes was regarded as a nonspecific effect of 5- 
 
HT ligands unrelated to the stress response. 
        
       Rotarod.  Rotarod performance was used to assess general motor function and was  
 








       Recording Data.  Any behavior involving a timed measure was recorded to the  
 
nearest hundredth of a second, with the exception of the rotarod, which was measured  
 
to the tenth of a second.  Any variable measured according to weight, such as eating and  
 




        Data collected in the tail pinch and the open field were analyzed using Multivariate  
 
Analysis of Variance (MANOVA).  Data collected on the rotarod were analyzed  
 
separately by univariate analysis (ANOVA).  Rotarod data were not included in the  
 
MANOVA because some animals were unable to meet the training criterion, resulting in a  
 


































       An analysis of tail pinch data revealed that oral behavior directed at food (OB w/ food)  
 
was the predominant behavioral response to tail pinch stress.  On average, animals spent  
 
approximately 80 of a possible 240 seconds engaged in oral behavior directed at food.   
 
However, 36% of the animals did not exhibit any OB w/ food under saline conditions.   
 
Inclusion of these zeroes in our initial analysis resulted in an inflated error term, and a  
 
concomitant reduction of statistical significance in our analyses.  In experiments 4 and 5, this  
 
inflation led to a diminution of statistical significance with regard to DOI relative to saline.   
 
Thus, a post-hoc exclusionary criterion of 2 seconds was set for OB w/ food in the saline  
 
condition.  To be included in the secondary (post-culling) analyses, an animal must have  
 
exhibited more than 2 seconds of OB w/ food in the saline condition.  Animals not meeting  
 
this criterion were culled from further analyses.  Results of both analyses are included in the  
 
following sections.  For the sake of simplicity, excluded animals will be referred to as non- 
 
responders in the subsequent discussion.               
       
Statistical Analysis 
        
       Statistical analyses were conducted using SPSS (Statistical Package for the Social  
 
Sciences, V. 10.0 for Windows).  Tail pinch and open field behaviors were analyzed by  
 
MANOVA.  Rotarod data were analyzed separately by ANOVA.  
 
       Primary Analysis.  Prior to exclusion of non-responders, data were analyzed to  
 
determine if drug condition significantly affected behavioral responses to stress.  The  
 
results of each MANOVA are summarized in the following sections.  In each experiment,  
 
drug condition was the independent variable.  Dependent variables were outlined in  
 






of the exclusionary criterion, n for each experiment was as follows: 15 (Exp. 1), 16 (Exp  
 
2), 16 (Exp. 3), 15 (Exp. 4), and 16 (Exp. 5). 
 
       Secondary Analysis.  After implementing an exclusionary criterion, n for each  
 
experiment was reduced to the following: 12 (Exp. 1), 10 (Exp. 2), 10 (Exp. 3), 8 (Exp.  
 
4), and 10 (Exp. 5).  In an effort to achieve roughly equivalent n in each experiment,  
 
animals were added to supplement experiments 4 and 5, bringing the final n in these  
 
experiments to 11 and 13, respectively.  These animals were subject to identical  
 
methodological considerations given prior groups and were assigned to first-day drug  
 
conditions in a manner designed to compensate for excluded data.        
        
Experiment 1 
 
       Primary Analysis.  Experiment 1 established a dose-response curve for DOI.  The  
 
overall MANOVA was significant [F(39, 107)=2.84, p=.000], using Wilk’s criterion.   
 
The resulting univariate ANOVAs for each dependent variable are included in Table 3.   
 
Variables that differed significantly across at least one experimental condition are  
 
denoted with an asterisk.          
 
       Secondary Analysis.  As was the case in the primary analysis, the overall MANOVA  
 
for the four experimental conditions was found to be significant [F(39,96)=2.38, p=.000].   
 
The secondary univariate analysis is summarized in Table 3.  
 
 Table 3: Experiment 1 Univariate ANOVAs by Behavior 
 
                                                                          Primary          Secondary  
 
Behavior df F  p  F  p  
Eating 3 1.77 0.16 1.95 0.14 
Gnawing 3 0.60 0.62 0.65 0.59 
Oral Behavior Directed 
at Food* 








Oral Behavior Not 
Directed at Food 
3 0.23 0.88 1.64 0.19 
Grooming 3 1.35 0.27 2.52 0.07 
Vocalizations 3 1.63 0.19 1.00 0.40 
Boli (Tail Pinch) 3 0.67 0.57 0.73 0.54 
Line Crosses 3 2.67 0.06 2.70 0.057 
Rearing* 3 12.05 0.000 10.60 0.000 
Head Shakes* 3 6.65 0.001 5.21 0.002 
Body Shakes 3 2.15 0.10 2.20 0.10 
Boli (Open Field) 3 0.30 0.82 0.00 1.00 
Freezing 3 2.25 0.09 2.31 0.09 
 
       Experiment 1 post hoc analysis.  Primary post hoc analyses revealed that DOI altered  
 
responding in the following three behavioral variables: oral behavior directed at food,  
 
rearing, and head shakes.  Secondary analysis revealed significant findings for the same  
 
three variables: oral behavior directed at food, rearing, and head shakes.   
         
        Oral behavior directed at food (Figures 5 and 6).  Primary and secondary analysis  
 
generated statistically similar findings with respect to oral behavior directed at food.  OB w/  
 
food was reduced by the middle (pprimary=.010; psecondary=.003) and high (pprimary=.002;  
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psecondary=.000) doses of DOI, relative to saline.  OB w/ food was also reduced, relative to  
 
low-dose DOI, by middle (pprimary=.032; psecondary=.012) and high (pprimary=.009; psecondary=.002)  
 
doses of DOI.   
Drug Condition




























Figure 6: OB w/ Food (Exp. 1 Secondary Analysis) 
 
       Rearing (Figures 7 and 8).  As was the case with OB w/ food, primary and secondary  
 
analyses of rearing yielded similar results.   Rearing was reduced by middle (pprimary=.000;  
 
psecondary=.001) and high (pprimary=.001;psecondary=.001) doses of DOI, relative to saline.   
Drug Condition
























Rearing was also reduced by middle (pprimary=.000; psecondary=.000) and high  
 
(pprimary=.000; psecondary=.000) doses of DOI, relative to low-dose DOI.   
Drug Condition
















        
Figure 8: Rearing (Exp. 1 Secondary Analysis) 
 
       Head Shakes (Figures 9 and 10). Head shaking was increased by the middle dose of  
 
DOI relative to saline (pprimary=.000; psecondary=.000), low-dose DOI (pprimary=.001;  
 
psecondary=.003), and high-dose DOI (pprimary=.003; psecondary=.007).  Frequency of head shakes  
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was not affected by the low or high doses of DOI, relative to controls, in either the primary  
 
or secondary analyses.        
Drug Condition





















Figure 10: Head Shakes (Exp.1 Secondary Analysis) 
 
Experiment 2  
 
       Primary/secondary Analyses.  Experiment 2 examined the dose-response profile of  
 
the 5-HT2A antagonist, spiperone.  Primary analysis by MANOVA revealed that  
 
spiperone did not significantly alter behavioral responding when administered alone  
 
[F(36,145)=1.35; p=.11].  This was also the case for the secondary MANOVA,  
 




       Primary/secondary Analyses.  Experiment 3 evaluated the possible behavioral  
 
effects of the 5-HT2C antagonist, SDZ SER 082.  As with spiperone, 5-HT2C antagonism  
 
alone did not affect behavioral responses to stress based on the primary analysis by  
 
MANOVA  [F(33,148)=1.02, p =.45].  Similarly, the secondary MANOVA was not  
 










       Dose Selection.  Experiment 4 examined the possibility that the effects of DOI on  
 
stress-induced behavior might be reduced using a single selective antagonist.  Doses for  
 
DOI, spiperone (2A antagonist), and SDZ SER 082 (2C antagonist) were chosen based  
 
on findings from Experiments 1, 2, and 3.  In the case of DOI, the middle dose (0.5  
 
mg/kg) was selected based on the fact that this dose of DOI produced behavioral effects  
 
that were statistically indistinguishable from high-dose DOI.  Therefore, it was  
 
reasonable to conclude that behaviors affected by the middle dose of DOI had a greater  
 
likelihood of being antagonized in Experiment 4. 
 
       Appropriate doses of spiperone and SDZ SER 082 were determined based on   
 
findings from Experiments 2 and 3.  Because neither drug was shown to alter  
 
behavioral responding when administered alone, the highest dose (1.0 mg/kg) for each  
 
drug was selected. 
 
       Analyses.  The primary MANOVA for the four experimental conditions was  
 
significant, [F(39,131)=3.24, p=.000], as was the secondary MANOVA [F(36,86)=1.82,  
 
p=.012].  The resulting univariate ANOVAs are included in Table 4 below.  Behaviors  
 
that differed significantly across at least one experimental condition are denoted with an  
 
asterisk.       
 
Table 4: Experiment 4 Univariate ANOVAs by Behavior 
 
                                                                             Primary            Secondary  
 
Behavior df F  p  F  p  
Eating 3 0.25 0.86 0.60 0.62 
Gnawing 3 0.73 0.54 0.05 0.99 
Oral Behavior 
Directed at Food* 








Oral Behavior Not 
Directed at Food 
3 1.73 0.17 0.80 0.50 
Grooming 3 2.18 0.10 0.37 0.77 
Vocalizations 3 1.85 0.15 2.03 0.13 
Boli (Tail Pinch) 3 0.71 0.55 0.88 0.46 
Line Crosses* 3 7.52 0.00 3.26 0.03 
Rearing* 3 5.65 0.00 2.66 0.06 
Head Shakes* 3 7.38 0.00 4.44 0.00 
Body Shakes 3 1.00 0.40 - - 
Boli (Open Field) 3 18.83 0.59 0.50 0.69 
Freezing* 3 0.64 0.00 5.07 0.00 
 
       Experiment 4 Post Hoc Analyses.  Primary and secondary post hoc analyses generated  
 
different results for Experiment 4.  Primary post hoc analyses revealed that drug  
 
conditions altered four behavioral variables: line crosses, rearing, head shakes, and freezing.   
 
Secondary post hoc analyses also indicated that drug conditions affected responding across  
 
four behavioral variables.  However, these four variables differed slightly from the primary  
 
post hoc analyses: oral behavior directed at food, line crosses, head shakes, and freezing.   
       
       Oral Behavior Directed at Food (Figure 11).  Secondary analysis revealed the OB  
 
w/food was reduced, relative to saline, by DOI (p=.007), DOI + spiperone (p=.008), and  
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DOI + SDZ SER 082 (p=.007).  That is, neither antagonist reversed the DOI-induced  
 
reductions in oral behavior.   
 
       Line crosses (Figures 12 and 13).  In both the primary and secondary analyses,  
 
injections of DOI + SDZ SER 082 resulted in decreased line crossing relative to saline  
 
(pprimary=.000; psecondary=.012).  In the primary analysis, injections of DOI + SDZ SER 082  
 
were also shown to decrease line crossing relative to DOI alone (p=.026).  Primary analysis  
 
also showed that DOI + spiperone increased line crossing relative to DOI (p=.044).  
Drug Condition




















Figure 12: Line Crosses (Exp. 4 Primary Analysis) 
Drug Condition































       Rearing (Figure 14). Primary analysis indicated that injections of DOI reduced rearing,  
 
relative to saline (p=.006), as did DOI + spiperone (p=.008), and DOI + SDZ SER 082  
 
(p=.000).  Neither antagonist was able to reverse the DOI-induced reduction of rearing. 
Drug Condition


















Figure 14: Rearing (Exp. 4 Primary Analysis) 
 
       Head shakes (Figures 15 and 16).  In the primary and secondary analyses, DOI  
 
increased head shakes relative to both saline (pprimary=.006; psecondary=.004) and DOI +  
 
SDZ SER 082 (pprimary=.006; psecondary=.004), as did DOI + spiperone (p=.000), which  
 
suggests that the 5-HT2C antagonist was able to reverse DOI-induced head shaking.  Both  
Drug Condition




























primary and secondary analyses indicated spiperone was ineffective in blocking DOI- 
 
induced head shaking. 
 
Drug Condition























Figure 16: Head Shakes (Exp. 4 Secondary Analysis) 
 
       Freezing (Figures 17 and 18).  Primary and secondary analyses generated the same  
 
findings with respect to freezing.  Injections of DOI + SDZ SER 082 resulted in increased  
 
freezing relative to saline (pprimary=.000; psecondary=.006), DOI (pprimary=.000;  
 
psecondary=.001), and DOI + spiperone (pprimary=.000; psecondary=.004).      
Drug Condition






































        
Figure 18: Freezing (Exp. 4 Secondary Analysis) 
 
Experiment 5 
        
       Experiment 5 examined the effects of DOI on stress-induced behavior when co- 
 
administered with a combination of 5-HT2A and 5-HT2C antagonists.  The overall primary  
 
MANOVA was significant F(39,142)=7.48, p=.000], as was the secondary MANOVA  
 
[F(39,107)=3.735, p=.000].  As before, the resulting univariate ANOVAs from each  
 
analysis are included in Table 5 below.  Significant variables are denoted with an  
 
asterisk.   
 
Table 5: Experiment 5 Univariate ANOVAs by Behavior 
 
                                                                               Primary      Secondary  
 
Behavior df F  p  F  p  
Eating 3 0.57 0.63 0.85 0.48 
Gnawing* 3 0.94 0.43 2.73 0.05 
Oral Behavior 
Directed at Food* 
3 2.22 0.10 6.24 0.00 
Oral Behavior Not 
Directed at Food* 
3 11.44 0.00 5.15 0.00 
Grooming* 3 3.74 0.02 1.07 0.37 
Vocalizations 3 2.01 0.12 0.11 0.95 








Line Crosses* 3 24.47 0.00 17.73 0.00 
Rearing* 3 18.87 0.00 15.60 0.00 
Head Shakes* 3 17.55 0.00 7.67 0.00 
Body Shakes* 3 9.92 0.00 3.49 0.02 
Boli (Open Field) 3 52.64 0.09 1.64 0.19 
Freezing* 3 2.24 0.00 32.36 0.00 
 
       Experiment 5 Post Hoc Analysis.  Primary post hoc analysis revealed that drug  
 
conditions altered responding across seven behavioral variables: oral behavior without  
 
food, grooming, line crosses, rearing, head shakes, body shakes, and freezing.   
 
Secondary post hoc analysis revealed that drug conditions significantly altered  
 
responding in eight behavioral variables: gnawing, oral behvaior directed at food, oral  
 
behavior not directed at food, line crosses, rearing, head shakes, body shakes, and  
 
freezing.   
 
       Gnawing (Figure 19).  Secondary analysis showed that gnawing was reduced,  
 
relative to saline, by spiperone + SDZ SER 082 (p=.038) and DOI + spiperone + SDZ  
 
SER 082 (p=.047).     
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       Oral Behavior Directed at Food (Figure 20).  Based on secondary analysis, oral  
 
behavior directed at food was reduced, relative to controls, by DOI alone (p=.020), DOI  
 
+ spiperone (p=.002), and DOI + spiperone + SDZ SER 082 (p=.004).  
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Figure 20: OB w/ Food (Exp. 5 Secondary Analysis) 
 
       Oral Behavior Not Directed at Food (Figures 21 and 22).  Both analyses generated  
 
similar findings with respect to oral behavior not directed at food.  OB w/o food was  
 
reduced, relative to saline, by spiperone + SDZ SER 082 (pprimary=.000; psecondary=.016)  
 
and DOI + spiperone + SDZ SER 082 (pprimary=.000; psecondary=.009).  This behavior was  
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also significantly reduced, relative to DOI alone, by spiperone + SDZ SER 082 (pprimary=.007;    
 
psecondary=.007), and DOI + spiperone + SDZ SER 082 (pprimary=.002; psecondary=.004).  
Drug Condition




























Figure 22: OB w/o Food (Exp. 5 Secondary Analysis) 
 
       Grooming (Figure 23).  Primary analysis revealed that spiperone + SDZ SER 082  
 





















Figure 23: Grooming (Exp.5 Primary Analysis) 
        
       Line Crossing (Figures 24 and 25).  Each analysis generated identical findings with  
 






spiperone + SDZ SER 082 (pprimary=.000; psecondary=.000) and DOI + spiperone + SDZ  
 
SER 082 (pprimary=.000; psecondary=.000).  Line crossing was also significantly reduced,  
 
relative to DOI alone, by spiperone + SDZ SER 082 (pprimary=.000; psecondary=.000) and  
 
DOI + spiperone + SDZ SER 082 (pprimary=.000; psecondary=.000). 
Drug Condition

























Figure 24: Line Crosses (Exp. 5 Primary Analysis) 
 
Drug Condition

























Figure 25: Line Crosses (Exp. 5 Secondary Analysis) 
 
       Rearing (Figures 26 and 27).  Both analyses indicated that rearing was reduced,  
 





























Figure 26: Rearing (Exp. 5 Primary Analysis) 
Drug Condition

















               
Figure 27: Rearing (Exp. 5 Secondary Analysis) 
 
       Head Shakes (Figures 28 and 29).  Primary and secondary analyses revealed similar  
 
results with respect to head shakes.  Injections of DOI increased head shakes relative to  
 
saline (pprimary/secondary=.000), spiperone + SDZ SER 082 (pprimary/secondary=.000), and DOI +  
 





























Figure 28: Head Shakes (Exp. 5 Primary Analysis) 
Drug Condition




















        
Figure 29: Head Shakes (Exp. 5 Secondary Analysis) 
 
       Body Shakes (Figures 30 and 31).  Once again, the primary and secondary analyses  
 
yielded similar findings with respect to open field behavior.  DOI increased body shakes  
 
relative to saline (pprimary=.000; psecondary=.008), spiperone + SDZ SER 082 (pprimary=.000;  
 
psecondary=.031), and DOI + spiperone + SDZ SER 082 (pprimary=.000; psecondary=.008).  These  
 
findings suggest that DOI-induced head and body shakes can be attenuated by a combination  
 






and other open field behaviors, it may simply be the case that the administration of multiple  
 
antagonists resulted in sedation.  This issue will be discussed in later sections. 
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Figure 30: Body Shakes (Exp. 5 Primary Analysis) 
Drug Condition





















Figure 32: Body Shakes (Exp. 5 Secondary Analysis) 
        
       Freezing (Figures 33 and 34).  Primary and secondary analyses produced similar  
 
findings in the case of freezing behavior.  Spiperone + SDZ SER 082 increased freezing  
 
relative to saline (pprimary/secondary=.000) and DOI (pprimary/secondary=.000).  DOI + spiperone +  
 
SDZ SER 082 also increased freezing relative to saline (pprimary/secondary=.000) and DOI  
 


























Figure 33: Freezing (Exp. 5 Primary Analysis) 
Drug Condition



















Figure 34: Freezing (Exp. 5 Secondary Analysis) 
 
       Rotarod Data.  In all five experiments, ANOVAs for rotarod data failed to achieve  
 
statistical significance.  However, in Experiment 5, aberrations were seen in animals injected  
 
with spiperone + SDZ SER 082, as well as DOI + spiperone + SDZ SER 082.  In  
 
both instances, animals’ time spent on the rotarod was decreased (nonsignificantly) relative  
 
to DOI alone and controls.  It is worthy of note that any deviation from normal rotarod  
 







aforementioned groups exhibited behavior suggestive of sedation in both the tail pinch and  
 


















































       The current study was conducted in an effort to further examine the influence of  
 
serotonergic ligands on stress responding in rats.  Eight hypotheses were tested over the 
 
course of five experiments.  The following discussion will examine each of the hypotheses  
 
based on findings from the secondary analyses presented in the previous section. 
        
Hypothesis 1: The Non-selective 5-HT2 Agonist, Injected Subcutaneously, Will  
Decrease Tail Pinch-induced Stress Responding in Rats 
 
       Both the middle and high doses of DOI were shown to reduce tail pinch-induced oral  
 
behavior directed at food (Exp. 1,4, and 5).  This replicates the previously published finding  
 
from our laboratory that DOI decreases stress-evoked oral behavior (Hawkins, et al., 2002).   
 
The effects of DOI on oral behavior can be interpreted in various ways.  The current paper  
 
will examine the findings in the context of published work regarding the effects of DOI in  
 
various models of stress and anxiety.  The possibility that the behavioral effects of DOI are  
 
the result of increased satiety, or of a nonspecific malaise, will also be examined.      
 
       DOI’s Effect on Stress Responding.  Results of Experiment 1, 4, and 5 indicate that  
 
DOI dose-dependently reduces stress-evoked oral behavior directed at food.  This finding is  
 
consistent with much of the existing literature regarding 5-HT2A/2C agonists and their effects  
 
on stress and anxiety.  Although these studies employ different models of stress, it is  
 
possible to generalize the findings in terms of the general effects of 5-HT2A/2C agonists on  
 
paradigm-specific behavior.     
 
       Peripheral injections of DOI have been shown to increase punished responding in the  
 
four-plate test, a finding indicative of decreased sensitivity to physical stress (Dhonnchadha,  
 







agonists have also been shown to decrease escape behavior in models involving aversive  
 
stimuli, such as direct stimulation of the dorsal periaqueductal gray and exposure to the  
 
elevated T-plus maze (de Paula Soares, 2004; Mora, Netto, and Graeff, 1997; Zangrossi,  
 
et al., 2001; Graeff, et al., 1993).  These findings, coupled with a replicated demonstration  
 
that DOI reduces stress-evoked oral behavior in our laboratory, suggest that 5-HT2A/2C  
 
agonists decrease behavioral responding to physical stress.         
 
       DOI and Satiety.  It is possible that the effects of DOI are the result of an alteration in  
 
behavioral satiety sequences in rodents. Although the present study did not compare eating  
 
in tail pinch animals versus unstressed controls, other studies have demonstrated that tail  
 
pinch stress increases ingestive behavior in rodents (Levine and Morley, 1981; Koch and  
 
Bodnar, 1993; Szechtman and Hall, 1980; Heinrichs, et al., 1992).  Stress-induced increases  
 
in food intake are blockable with central and peripheral administration of DOI and other 5- 
 
HT2A/2C agonists (Currie, Coiro, Niyomchai, Lira, and Farahmand, 2002; Currie, Saxena, and  
 
Tu, 1999; Currie and Coscina, 1997).  These behavioral effects have been attributed to the  
 
ability of 5-HT2 agonists to activate the HPA axis, thereby slowing gastric emptying and  
 
inducing satiety (Raghavendra and Kulkarni, 2000; Ferrari, Pelloni, and Guiliani, 1992;  
 
Baker, Duggan, Barber, and Booth, 1998; Francis, Critchley, Dourish, and Cooper, 1995).  
 
       Although the current study consistently demonstrated that DOI reduces oral behavior  
 
directed at food, there was no statistically significant DOI-induced reduction in eating or  
 
gnawing.  Thus, the suggestion that DOI induced satiety in the current study must be made  
 
cautiously.  We did observe a dose-dependent trend toward reduced eating following DOI  
 
injections in Experiment 1.  Low, medium, and high doses of DOI reduced eating, relative to  
 






demonstrated that DOI dose-dependently reduces eating and gnawing (Hawkins, et al.,  
 
2002).   
 
       Drug-induced Malaise.  5-HT and related compounds are known to induce malaise, a  
 
behavioral profile typified by nausea, tremor, and fatigue (DeVry, Eckel, Kuhl, and  
 
Schreiber, 2000).  This is a potential confound when interpreting the effects of DOI on  
 
ingestion and oral behavior, as the anorectic behavioral profile seen in these studies may  
 
indicate nausea, rather than a decrease in anxiety (DeVry, et al., 2000).  A study involving  
 
the co-administration of DOI and an anti-emetic compound might be of utility in determining  
 
if nausea is responsible for the behavioral effects produced by 5-HT2 agonists. 
 
Hypothesis 2: The Effect of DOI On Tail Pinch-induced Stress Responding Will be  
Reduced by Peripheral Co-administration of the Selective 5-HT2A Antagonist, 
Spiperone 
 
       Experiment 4 examined the effects of co-administration of a single antagonist with DOI.   
 
Spiperone did not alter the behavioral effects of DOI in the tail pinch condition.  This  
 
finding is inconsistent with previous reports that spiperone blocks DOI-induced hypophagia   
 
in tail-pinched rats (Samarghandian, Ohata, Yamauchi, and Shibasaki, 2003).  It should be  
 
noted that the Samarghandian, et al. study employed intracerebroventricular injections of  
 
spiperone.  As such, it is possible that the permeability of the blood-brain to spiperone may  
 
be a factor moderating the drug’s effects.  Although spiperone is known to cross the BBB,  
 
definitive data regarding the degree to which spiperone crosses this barrier are not currently  
 












Hypothesis 3: The Effect of DOI on Tail Pinch-induced Stress Responding Will be  
Reduced by Peripheral Co-administration of the Selective 5-HT2C Antagonist, SDZ  
SER 082 
        
       Experiment 4 failed to produce any evidence that SDZ SER 082 altered behavioral  
 
responding to tail pinch and DOI injection.  Although relatively few studies employing SDZ  
 
SER 082 have been published, this finding is inconsistent with reports that SDZ SER 082  
 
blocks 5-HT-induced behavior in certain models of stress (de Paula Soares and Zangrossi,  
 
2004).  Further evidence of SDZ SER 082’s ability to alter oral and ingestive behavior has  
 
been demonstrated in studies involving 5-HT2-selective compounds (Castro, et al., 2003,  
 
Castro, et al., 2002, Currie, Coiro, Nyomchai, Lira, and Farahmand, 2002 ).  However, none   
 
of these studies examined stress-evoked oral behavior, as was the case in the current study.   
 
Additionally, these studies involved central, rather than peripheral, injections of 5-HT2  
 
ligands.  Thus, the possibility exists that the effects of SDZ SER 082 are limited by the  
 
compound’s ability to cross the BBB.  Still, SDZ SER 082 has been shown to alter  
 
behavioral responding when administered peripherally (Goudie, Smith, Taylor, Taylor, and  
 
Tricklebank, 1998; Mora, Netto, and Graeff, 1997).  While 5-HT2C receptors are known to  
 
exist in the periphery, it is more plausible that the effects of SDZ SER 082 on anxiety and  
 
stress are centrally-mediated, suggesting permeability of the BBB to spiperone (Mora, Netto,  
 
and Graeff, 1997).  Conclusive data regarding the permeability of the BBB to SDZ SER 082  
 
are not currently available, however.        
      
Hypothesis 4: Spiperone and SDZ Will Have No Effect on Stress Responding When  
Administered Alone 
 
       Experiments 2 and 3 examined the effects of spiperone and SDZ SER 082, injected  
 







neither compound altered behavioral responding when injected alone.  This is compatible  
 
with previous findings that 5-HT2A antagonists are ineffective in altering anxious behavior  
 
evoked by stressors (Gleeson, Ahlers, Mansbach, Foust, and Barrett, 1989; Griebel, Perrault,  
 
and Sanger, 1997; Setem, Pinheiro, Motta, Morato, and Cruz, 1999, Bourin and Hascoet,  
 
2003).  Conversely, various studies have demonstrated that 5-HT2A and 5-HT2C antagonists,  
 
injected alone, decrease stress responding in various rodent models (Stutzmann, et al., 1991,  
 
Motta, Maisonnette, Morato, Castrechini, and Brandao, 1992, Costall and Naylor, 1995;  
 
Mora, et al., 1997; Graeff, Netto, and Zangrossi, 1998; Gacsalyi, et al., 1997, Griebel, et al.,  
 
1997; Dekeyne, Denorme, Monneyron, and Millan, 2000).  However, findings that these  
 
antagonists increase stress responding have been reported also (Olivier, et al., 1998, Setem,  
 
et al., 1999, Maisonette, et al., 2000).  The discrepancy in these findings may be partially  
 
attributable to the nature of the stressor employed in these studies, an issue that has been  
 
addressed in the Deakin and Graeff theory of 5-HT and anxiety (discussed below).        
        
Hypothesis 5: Simultaneous Administration of Spiperone and SDZ SER 082 Will 
Result in Greater Antagonism of DOI’s Effects Than That of Either Antagonist 
Administered Alone 
 
       Experiment 5 examined the possibility that co-administration of spiperone and SDZ  
 
SER 082 would alter DOI-induced behavioral responding in a manner distinguishable from  
 
the effects produced by either antagonist alone.  Spiperone + SDZ SER 082 decreased  
 
behavioral responding across several variables in the tail pinch stressor condition and in the  
 
open field: gnawing, oral behavior directed at food, oral behavior not directed at food, line  
 
crossing, and rearing.  Additionally, spiperone + SDZ SER 082 increased freezing behavior  
 
in the open field.  These effects were observed when these antagonists were injected  
 






findings are indicative of decreased motor activity.  Casual observation of these animals  
 
during testing, coupled with the behavioral findings above, suggest a pharmacological, rather  
 
than physiological effect of 5-HT2 antagonists on behavioral responding.   
 
       Antagonism of Head and Body Shakes.  In addition to altering the behavioral  
 
variables discussed in the previous section, injection of spiperone + SDZ SER 082 was  
 
shown to abolish DOI-induced head shakes and body shakes.  This finding is consistent with  
 
previous reports from our laboratory and others that head and body shakes are mediated at  
 
the level of the 5-HT2 receptor (Hawkins, et al., 2002; Marek, 2003; Mitchell, Fairhall,  
 
Fretcher, and Redfern, 2003; Koskinen, Haapalinna, and Sirvio, 2003).  Combined injections  
 
of spiperone and SDZ SER 082 were equally as effective as SDZ SER 082, as they both  
 
abolished head shakes.  However, the same combination of antagonists abolished body  
 
shakes, whereas individual antagonists were without effect.  Thus, it would appear that  
 
simultaneous administration of 5-HT2 antagonists was more effective than either antagonist  
 
injected alone.  This finding should be interpreted cautiously, as it is possible that the  
 
pharmacological effects of multiple antagonists outweigh their apparent antagonistic effects.    
        
Hypothesis 6: Subcutaneous Injection of DOI Will Have an Anxiolytic Effect on  
Animal Behavior in the Open Field 
 
       DOI consistently reduced rearing, while increasing the number of head shakes, in the  
 
open field.  DOI also increased body shakes, relative to saline, in experiment 5.   
 
       Rearing. DOI’s effects on reducing rearing can be interpreted alternatively as a decrease  
 
in exploratory behavior (anxiogenesis), a decrease in escape behavior (anxiolysis), or  
 
general motor impairment.  It seems unlikely that this effect on rearing is due to motor  
 






Thus, the third interpretation will not be addressed in the current discussion.  A  
 
preponderance of rodent studies classify reductions in rearing as an indication of  
 
anxiogenesis (To and Bagdy, 1999; Rogers, et al., 2000; Singh, Jaiswal, Singh, and  
 
Bhattacharya, 1998; Osborn, Yu, Gabriel, and Weinberg, 1998; Broderick, Hope, and  
 
Jeannot, 1998; Cornwell-Jones, et al., 1992).  In rare cases, reductions in “vigilant” rearing,  
 
whereby an animal rears in response to a predator’s odor, have been reported as an anxiolytic  
 
effect (Dielenberg and McGregor, 2001).  Given the lack of evidence that DOI induces  
 
motor impairment, it is concluded that DOI alters rearing in a manner consistent with an  
 
anxiogenic behavioral profile.  This finding stands in contrast to the hypothesis that DOI  
 
would reduce stress responding to tail pinch, a discrepancy that may be accounted for by the  
 
Deakin and Graeff theory of 5-HT and anxiety. 
 
       Dual-activation Theory of 5-HT.  The Deakin and Graeff theory of 5-HT and anxiety  
 
proposes that two serotonergic pathways selectively mediate distinct physiological responses  
 
to distal and proximal threats.  The former pathway is composed of the dorsal raphe nuclei,  
 
which innervate areas of the amygdala and frontal cortex.  Upon activation, this 5-HT 
 
pathway is thought to produce anxiogenic behavior in response to distal threats.  The latter  
 
5-HT pathway, composed of the dorsal raphe and its connections to the periventricular and  
 
periaqueductal gray matter, is thought to produce an anxiolytic response to unconditioned  
 
proximal threats.  Although the current study was not explicitly designed to distinguish  
 
between proximal and distal threats, it is reasonable to conclude that tail pinch stress may be 
 
classified as a stimulus that produces unconditioned fear by way of proximal threat.  Similar  
 
parallels can be drawn between the open field stressor and the distal threat of the Deakin and  
 






environment that is not characterized by an immediate physical threat to the animals involved.       
 
       The findings of the current study are consistent with the dual-activation theory in that   
 
DOI was shown to reduce stress responding to a proximal threat (tail pinch) and increase  
 
anxiogenic behavior in the open field.  However, further examination of selective  
 
serotonergic compounds in experimental models designed to accurately represent the  
 
constructs of proximal and distal threat is warranted. 
 
       Head and Body Shakes.  DOI consistently elevated the frequency of head and body  
 
shakes when administered in medium and high doses.  This effect has been observed in our  
 
laboratory and others (Hawkins, et al., 2002; Marek, 2003; Mitchell, Fairhall, Fretcher, and  
 
Redfern, 2003; Koskinen, Haapalinna, and Sirvio, 2003; Whitton, Sarna, Datla, and Curzon;  
 
Wettstein, host, and Hitchcock, 1999) and is generally regarded as an effect of 5-HT2  
 
agonists unrelated to stress.  
        
Hypothesis 7: The Effect of DOI on Open Field Behavior Will be Reduced by  
Spiperone, SDZ SER 082, or a Combination of the Two Antagonists 
 
       Experiments 4 and 5 examined the effects of 5-HT2 antagonists on DOI-induced  
 
behavior.         
 
       Single Antagonist (Experiment 4).  Others have concluded that DOI’s effect on  
 
inducing head shakes is due to activation of the 5-HT2A receptor (Mitchell, et al., 2003;  
 
Islam, Thompson, Akhtar, and Handley, 2004; Marek, 2003; Izumi, et al., 2002; Kulikov, et  
 
al., 1997, Gauffre, Aguerre, Mormede, and Chaouloff, 1997, Dursun and Handley, 1996).   
 
Additional support for the role of the 5-HT2A receptor in mediating head shakes has come  
 
from studies of genetically-altered rats.  Central glucocorticoid receptor “knockdown” rats,  
 







of 5-HT2A protein mRNA in the hypothalamus and frontal cortex, as well as hypersensitivity  
 
to DOI-induced head shakes (Islam, et al., 2004).  The implications of this study are twofold:  
 
5-HT2A receptors are largely responsible for mediating head shakes, and that glucocorticoid  
 
receptors may regulate 5-HT2A receptor expression.  In Experiment 4 of the present study,  
 
however, the 5-HT2A antagonist spiperone did not block DOI-induced head shaking, while  
 
the 5-HT2C antagonist SDZ SER 082 completely abolished it.  As such, the current study  
 
indicates that the 5-HT2C receptor may also play a role in mediating head shaking in rodents.   
 
       Multiple Antagonists (Experiment 5).  Combined injections of spiperone + SDZ SER  
 
082 were shown to abolish DOI-induced head shakes and body shakes in Experiment 5.  This  
 
finding is consistent with reports that ketanserin, a 5-HT2A/2C antagonist, reverses DOI- 
 
induced head and body shakes (Dursun and Handley, 1996; Fone, Robinson, and Marsden,  
 
1991) Administration of spiperone + SDZ SER 082, as well as DOI + spiperone + SDZ SER  
 
082 also resulted in decreased line crossing and rearing and increased freezing time in the  
 
open field.  Informal observation of these animals, coupled with analyses of the  
 
aforementioned behaviors suggests a pharmacological effect of multiple antagonists, rather  
 
than a specific ability of these compounds to mediate stress-related behavior.   
        
Hypothesis 8: The Administration of DOI, Spiperone, SDZ SER 082 and  
Combinations Thereof, Will Not Impair General Motor Function, as Measured by  
Rotarod Performance and Ambulation in the Open Field 
 
       No combination of drugs was found to alter rotarod performance significantly.  However,  
 
co-administration of SDZ SER 082 and spiperone, as well as the co-administration of DOI,  
 
spiperone, and SDZ SER 082 seemed to produce motoric impairment.  Although the  
 
statistical analysis of rotarod data from these groups was not significant, there was a trend  
 






Experiment 5, the respective means for saline, OI 0.5, spiperone + SDZ SER 082, and DOI +  
 
spiperone + SDZ SER 082 were as follows: 29, 29, 20, and 17 of a possible 30 seconds.  As  
 
mentioned previously, any deficits in rotarod performance were rare in these experiments.   
 
The largest deviation from the rotarod time criterion in Experiments 1-4 was approximately  
 
5%, contrasted with the 34% and 44% deficits in total rotarod time observed after  
 
administration of spiperone + SDZ SER 082 and DOI + spiperone + SDZ SER 082 in  
 
Experiment 5.  
 
       In the open field also, the co-administration of SDZ SER 082 and spiperone, as well as  
 
the co-administration of DOI, spiperone, and SDZ SER 082, seemed to impair motor  
 
activity, as indicated by increased freeze time and decreases in rearing and line crossing.   
 































       The most consistent findings of the current study are that DOI attenuates rearing and  
 
oral behavior directed at food, while increasing the frequency of head and body shakes in the  
 
open field.  DOI’s dose-dependent effects on tail pinch-induced oral behavior indicate that  
 
this compound has the potential to reduce responding to proximal threats.  Conversely,  
 
DOI’s effects in the open field suggest an anxiogenic response to a novel, threatening  
 
environment.  The observation that DOI produced opposing effects in separate behavioral  
 
models may be accounted for by the 5-HT dual-activation theory, discussed previously  
 
(Graeff, et al., 1996).   
 
       Administration of spiperone, SDZ SER 082, or a combination of the two drugs, did not  
 
block the effects of DOI on oral behavior or rearing.  While DOI-induced head shaking was  
 
antagonized by co-administration of the 5-HT2C antagonist, SDZ SER 082, as well as by a  
 
combination of SDZ SER 082 and spiperone, it is concluded that neither antagonist was able  
 
to alter stress-related behavior induced by the administration of DOI.    
 
       Future research should be directed at elucidating the brain areas or peripheral structures  
 
that mediate relevant stress-induced behavior.  It may be necessary to selectively target brain  
 
areas of interest (such as the PVN), as blood-brain permeability remains a potential  
 
confound in studies involving peripheral injection of drugs.  Additionally, the development of  
 
agonists selective for the various 5-HT2 receptor subtypes which readily cross the BBB may  
 














Adamec, R., Bartoszyk, G.D., and Burton, P., (2004).  Effects of systemic injections of  
       Vilazodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor agonist, on  
       anxiety induced by predator stress in rats.  European Journal of Pharmacology, 504  
       (1-2), 65-77.       
       
Adamec, R., Creamer, K., Bartoszyk, G.D., Burton, P., (2004).  Prophylactic and  
       therapeutic effects of acute systemic injections of EMD 281014, a selective serotonin 2A  
       receptor antagonist on anxiety induced by predator stress in rats.  European Journal of  
       Pharmacology, 504 (1-2), 79-96. 
 
Ahlenius, C., Larsson, K., & Wijkstrom, A., (1991).  Behavioral and biochemical  
       effects of the 5-HT1A receptor agonists flesinoxan and 8-OH-DPAT in the rat.  European  
       Journal of Pharmacology, 200 (2-3), 259-266. 
 
Aizenberg, D., Gur, S., Zemishlany, Z., Granek, M., Jeczmien, P., & Weizman, A.,  
       (1997).  Mianserin, a 5-HT2A/2C and alpha 2 antagonist, in the treatment of sexual  
       dysfunction induced by serotonin reuptake inhibitors.  Clinical Neuropharmacology, 20  
       (3), 210-214. 
 
Andrews, P.L., Davis, C.J., Bingham, S., Davidson, H.I., Hawthorn, J., & Maskell,  
       L., (1990).  The abdominal visceral innervation and the emetic reflex: pathways,  
       pharmacology, and plasticity.  Canadian Journal of Physiology and Pharmacology, 68       
       (2), 325-345. 
 
Baker, B.J., Duggan, J.P., Barber, D.J., & Booth, D.A., (1998).  Effects of dl- 
       fenfluramine and xylamidine on gastric emptying of maintenance diet in freely feeding    
       rats.  European Journal of Pharmacology, 150 (1-2), 137-142. 
 
Berendsen, H.H., Jenck, F., &Broekkamp, C.L., (1989).  Selective activation of  
       5HT1A receptors induces lower lip retraction in the rat.  Pharmacology, Biochemistry,  
       and  Behavior, 33 (4), 821-827. 
 
Bourin, M., & Hascoet, M., (2003).  The mouse light/dark test.  European Journal of  
       Pharmacology, 463 (1-3), 55-65. 
 
Broderick, P.A., Hope, O., & Jeannot, P. (1998).  Mechanism of triazolo- 
       benzodiazepine and benzodiazepine action in anxiety and depression: behavioral studies  
       with concomitant in vivo CA1 hippocampal norepinephrine and serotonin release  
       detection in the behaving animal.  Neuropsychopharmacology and Biological Psychiatry,    
       22(2), 353-86. 
 







Cannon, W.B., (1929).  Bodily changes in pain, hunger, fear and rage; an account of  
       recent researches into the function of emotional excitement, by Walter B. Cannon.  2nd  
       edition.  New York, London: D. Appleton and Company. 
 
Castro, L., Athanazio, R., Barbetta, M., Ramos, A.C., Angelo, A.L., Campos, I., et al.,   
       (2003).  Central 5-HT2B/2C and 5-HT3 receptor stimulation decreases salt intake in  
       sodium-depleted rats.  Brain Research, 981 (1-2), 151-9. 
 
Castro, L., Maldonado, I., Campos, I., Varjao, B., Angelo, A.L., Athanazio, R.A., et  
       al., (2002).  Central administration of mCPP, a serotonin 5-HT(2B/2C) agonist, decreases  
       water intake in rats.  Pharmacology, Biochemistry, and Behavior, 72(4), 891-8.   
        
Chow-Green, J.M., Holscher, T.D., Dallman, M.F., & Akana, S.F., (2003).   
       Repeated stress in young and old 5-HT(2C) receptor knockout mice.  Physiology &  
       Behavior, 79 (2), 217-226. 
     
Chrousos, G.P., (1995).  The hypothalamic-pituitary-adrenal axis and immune- 
       mediated inflammation.  New England Journal of Medicine, 332 (20), 1351-1362.        
 
Clark, M.S., Sexton, T.J., McClain, M., Root, D., Kohen, R., & Neumaier, J.F., (2002).   
       Overexpression of 5-HT1B receptor in dorsal raphe nucleus using Herpes Simplex Virus  
       gene transfer increases anxiety behavior after inescapable stress.  Journal of      
       Neuroscience, 22 (11), 4550-4562. 
 
Cornwell-Jones, C.A., Palfai, T., Krasenbaum, D., Byer, E. Jr., Clark, R., & Kinnard,  
       K., (1992).  Housing influences exploration and social interaction of control and DSP-4- 
       treated rats.  Physiology and Behavior, 52(2), 271-6. 
        
Costall, B., & Naylor, R.J., (1995).  Behavioural interactions between 5- 
       hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying     
       rodent responding to aversive situations.  British Journal of Pharmacology, 116 (7),         
       2989-99. 
 
Cunningham, E.T. Jr., Bohn, M.C., & Sawchenko, P.E., (1990).  Organization of  
       adrenergic inputs to the paraventricular and supraoptic nuclei of the hypothalamus in the  
       rat.  Journal of Comparative Neurology, 292 (4), 651-667. 
 
Currie, P.J., Coiro, C.D., Niyomchai, T., Lira, A., & Farahmand, F., (2002).   
       Hypothalamic paraventricular 5-hydroxytryptamine: receptor-specific inhibition of NPY- 
       stimulated eating and energy metabolism.  Pharmacology, Biochemistry, and Behavior,    
       71 (4), 709-716. 
        
Currie, P.J., Saxena, N., & Tu, A.Y., (1999).  5-HT2A/2C receptor antagonists in the  
       paraventricular nucleus attenuate the action of DOI on NPY-stimulated eating.     






Currie, P.J., & Coscina, D.V., (1997).  Stimulation of 5-HT2A/2C receptors within  
       specific hypothalamic nuclei differentially antagonizes NPY-induced feeding.     
       Neuroreport, 8 (17), 3759-62. 
 
Davis, R., Whittington, R., & Bryson, H.M., (1997).  Nefazodone. A review of its  
       pharmacology and clinical efficacy in the management of major depression.  Drugs, 53  
       (4), 608-636. 
 
De Montigny, C., Pineyro, G., Chaput, Y., & Blier, P., (1992).  Electrophysiological  
       studies on the effect of long-term 5-HT reuptake inhibition on the function of 5-HT  
       neurons.  Clinical Neuropharmacology, 15 (1), 440A-441A. 
 
De Paula Soares, V., Zangrossi, H, Jr., (2004).  Involvement of 5-HT1A and 5-HT2  
       receptors of the dorsal periaqueductal gray in the regulation of the defensive behaviors  
       generated by the elevated T-maze.  Brain Research Bulletin, 64 (2), 181-188. 
 
De Vry, J., Eckel, G., Kuhl, E., & Schreiber, R., (2000).  Effects of serotonin 5-HT1  
       and 5-HT2 receptor agonists in a conditioned taste aversion paradigm in the rat.   
       Pharmacology, Biochemistry, and Behavior, 66(4), 797-802.  
 
Deakin, J.F., (1998).  The role of serotonin in panic, anxiety and depression.   
       International Clinical Psychopharmacology, 13 (4), S1-S5. 
 
Dekeyne, A., Denorme, B., Monneyron, S., & Millan, M.J., (2000).  Citalopram  
       reduces social interaction in rats by activation of serotonin 5-HT2C receptors.   
       Neuropharmacology, 39 (6), 1114-7. 
 
Derkach, V., Suprenant, A., & North, R.A., (1989).  5-HT3 receptors are membrane  
       ion channels.  Nature, 339 (6227), 706-709. 
         
Dhabbar, F.S., & McEwen, B.S., (1997).  Acute stress enhances while chronic stress  
       suppresses cell-mediated immunity in vivo: a potential role for leukocyte trafficking.   
       Brain, Behavior, and Immunity, 11 (4), 286-306.  
         
Dielenberg, R.A., & McGregor, I.S., (2001).  Defensive behavior in rats towards  
       predatory odors: a review.  Neuroscience and Biobehavioral Reviews, 25(7-8), 597-609. 
         
Done, C.J., & Sharp, T., (1992).  Evidence that 5-HT2 receptor activation decreases  
       noradrenaline release in rat hippocampus in vivo.  British Journal of Pharmacology, 107  
       (1), 240-245. 
         
Dursun, S.M., & Handley, S.L., (1996).  Similarities in the pharmacology of  
       spontaneous and DOI-induced head-shakes suggest 5HT2A receptors are active under  
       physiological conditions.  Psychopharmacology (Berlin), 128(2), 198-205. 






Duxon, M.S., Kennett, G.A., Lightowler, S., Blackburn, T.P., & Fone, K.C., (1997).  
       Activation of 5-HT2B receptors in the medial amygdala causes anxiolysis in the social  
       interaction test in the rat.  Neuropharmacology, 36 (4-5), 601-608. 
        
Erspamer, V., (1966).  Occurrence of indolealkylamines in nature.  Handbuch der  
       Experimentellen Pharmakologie, 294, 132-181. 
         
Feldman, J.M., & Lee, E.M., (1985).  Serotonin content of foods: effect on urinary  
       excretion of 5-hydroxyindoleacetic acid.  American Journal of Clinical Nutrition, 42 (4),  
       639-643. 
        
Feldman, S., Newman, M.E., & Weidenfeld, J., (2000).  Effects of adrenergic and  
       serotonergic agonists in the amygdala on the hypothalamo-pituitary-adrenocortical axis.   
       Brain Research Bulletin, 52 (6), 531-536. 
        
Ferrari, F., Pelloni, F., Giuliani, D., (1992).  B-HT 920 stimulates feeding and  
       antagonizes anorexia induced by ACTH and immobilisation.  European Journal of  
       Pharmacology, 210 (1), 17-22. 
         
Fone, K.C., Robinson, A.J., & Marsden, C.A., (1991).  Characterization of the 5-HT  
       receptor subtypes involved in the motor behaviours produced by intrathecal    
       administration of 5-HT agonists in rats.  British Journal of Pharmacology, 103(2), 1547-     
       55. 
        
Frances, H., Khidichian, F., & Monier, C., (1990).  Increase in the isolation-induced  
       social behavioural deficit by agonists at 5-HT1A receptors.  Neuropharmacology, 29 (2),  
       103-107. 
         
Francis, J., Critchley, D., Dourish, C.T., & Cooper, S.J., (1995).  Comparisons between  
       the effects of 5-HT and DL-fenfluramine on food intake and gastric emptying in the rat.   
       Pharmacology, Biochemistry, and Behavior, 50 (4), 581-5. 
         
Fregly, M.J., & Rowland, N.E., (1988).  Augmentation of isoproterenol-induced  
       drinking by acute treatment with certain dopaminergic agonists.  Physiology and    
       Behavior, 44 (4-5), 473-481.       
         
Fujikawa, M., Yamada, K., Nagashima, M., Domae, M., & Furukawa, T., (1996).   
       The new muscarinic M1-receptor agonist YM796 evokes yawning and increases    
       oxytocin secretion from the posterior pituitary gland in rats.  Pharmacology,    
       Biochemistry, and Behavior, 55 (1), 55-60. 
         
Fujikawa, M., Yamada, K., Nagashima, M., & Furukawa, T., (1995).  Involvement  
       of beta-adrenoceptors in regulation of the yawning induced by neuropeptides, oxytocin  
       and alpha-melanocyte-stimulating hormone, in rats.  Pharmacology, Biochemistry, and  






Gacsalyi, I., Schmidt, E., Gyertyan, I., Vasar, E., Lang, A., Haapalinna, A., et al.,  
       (1997).  Receptor binding profile and anxiolytic-type activity of deramciclane.  Drug  
       Development and Research, 40, 333-348. 
 
Gammans, R.E., Stringfellow, J.C., Hvizdos, A.J., Seidehamel, R.J., Cohn, J.B.,  
       Wilcox, C.S., et al., (1992).  Use of buspirone in patients with generalized anxiety  
       disorder and coexisting depressive symptoms. A meta-analysis of eight randomized,  
       controlled studies.  Neuropsychobiology, 25 (4), 193-201. 
         
Gartside, S.E., & Cowan, P.J., (1990).  Mediation of ACTH and prolactin responses  
       to 5-HTP by 5-HT2 receptors.  European Journal of Pharmacology, 179 (1-2), 103-109. 
         
Gauffre, J.C., Aguerre, S., Mormede, P., & Chaouloff, F., (1997).  Cortical  
       [3H]ketanserin binding and 5-HT2A receptor-mediated inositol phosphate production in  
       the spontaneously hypertensive rat and Lewis rat strains.  Neuroscience Letters, 236(2),  
       112-6. 
        
Gleeson, S,, Ahlers, S.T., Mansbach, R.S., Foust, J.M., Barrett, J.E., (1989).   
       Behavioral studies with anxiolytic drugs. VI. Effects on punished responding of drugs  
       interacting with serotonin receptor subtypes.  Journal of Pharmacology and  
       Experimental Therapeutics, 250 (3), 809-17. 
         
Goudie, A.J., Smith, J.A., Taylor, A., Taylor, M.A., & Tricklebank, M.D., (1998) 
       Discriminative stimulus properties of the atypical neuroleptic clozapine in rats: tests with  
       subtype selective receptor ligands.  Behavioural Pharmacology, 9 (8), 699-710. 
         
Graeff, F.G., Netto, C.F., Zangrossi, H. Jr., (1998).  The elevated T-maze as an  
       experimental model of anxiety.  Neuroscience and Biobehvaioral Reviews, 23(2), 237-   
       246. 
         
Graeff, F.G., Guimares, F.S., De Andrade, T.G., & Deakin, J.F. (1996).  Role of 5- 
       HT in stress, anxiety, and depression.  Pharmacology, Biochemistry, and Behavior, 54    
       (1), 129-141. 
         
Graeff, F.G., Silveira, M.C., Nogueira, R.L., Audi, E.A., Oliveira, R.M., (1993).  Role  
       of the amygdala and periaqueductal gray in anxiety and panic.  Behavioral Brain   
       Research, 58 (1-2), 123-31. 
         
Graeff, F.G., (1993).  Role of 5-HT in defensive behavior and anxiety.  Reviews in  
       the Neurosciences, 4 (2), 181-211. 
 
Greenshaw, A.J., & Silverstone, P.H., (1997).  The non-antiemetic uses of serotonin  
       5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications.  Drugs,  
       53 (1), 20-39. 






Griebel, G., Perrault, G., & Sanger, D.J., (1997).  A comparative study of the effects  
       of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse  
       models of anxiety.  Neuropharmacology, 36 (6), 793-802. 
         
Gross, C., Santarelli, L., Brunner, D., Zhuang, X., & Hen, R., (2000).  Altered fear  
       circuits in 5-HT1A receptor KO mice.  Biological Psychiatry, 48 (12), 1157-1163. 
         
Guillaume, V., Conte-Devolx, B., Szafarczyk, A., Malaval, F., Pares-Herbute, N.,  
       Grino, M., et al., (1987).  The corticotropin-releasing factor release in rat hypophysial  
       portal blood is mediated by brain catecholamines.  Neuroendocrinology, 46 (2), 143-    
       146. 
         
Guyton, A.C., & Hall, J.E. (Eds.). (1996).  Textbook of medical physiology. 9th  
       edition.  Philadelphia: Saunders. 
         
Haller, J., and Bakos, N. (2002).  Stress-induced social avoidance: a new model of  
       stress-induced anxiety?  Physiology and Behavior, 77 (2-3), 327-332. 
         
Hawkins, M.F., Uzelac, S.U., Baumeister, A.A., Hearn, J.K., Broussard, J.I., &  
       Guillot, T.S., (2002).  Behavioral responses to stress following central and peripheral  
       injection of the 5-HT2 agonist DOI.  Pharmacology, Biochemistry, and Behavior, 73 (3),  
       537-544. 
         
Heilig, M., (2004).  The NPY system in stress, anxiety and depression.  Neuropeptides,  
       38 (4), 213-224.        
         
Heinrichs, S.C., Cole, B.J., Pich, E.M., Menzaghi, F., Koob, G.F., Hauger, R.L.,  
       (1992).  Endogenous corticotropin-releasing factor modulates feeding induced by  
       neuropeptide Y or a tail-pinch stressor.  Peptides, 13 (5), 879-884. 
         
Hemrick-Luecke, S.K., & Evans, D.C., (2002).  Comparison of the potency of MDL  
       100,907 and SB 242084 in blocking the serotonin 5-HT2 receptor agonist-induced  
       increases in rat serum corticosterone concentrations: evidence for 5-HT2A receptor  
       mediation of the HPA axis.  Neuropharmacology, 42 (2), 162-169. 
         
Herberg, L.J., & Wishart, T.B., (1980).  Selective permeation of the blood-brain barrier as a     
       cause of the anomalous properties of 'atypical'neuroleptics.  Pharmacology,  
       Biochemistry, and Behavior, 12 (6), 871-3. 
        
Herman, J.P, Prewitt, C.M., & Cullinan, W.E., (1996).  Neuronal circuit regulation  
       of the hypothalamo-pituitary-adrenocortical stress axis.  Critical Reviews in     
       Neurobiology, 10 (3-4), 371-394. 








Higgins, G.A., Kilpatrick, G.J., Bunce, K.T., Jones, B.J., & Tyers, M.B., (1989).   
       5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced  
       emesis in the ferret.  British Journal of Pharmacology, 97 (1), 247-255. 
        
Hodges, J.R., (1984).  The hypothalamo-pituitary-adrenocortical system.  British  
       Journal of Anaesthesia, 56 (7), 701-710.  
         
Honn, K.V., & Chavin, W., (1977).  In vitro temporal cAMP and cortisol responses  
       to ACTH by the normal human adrenal gland.  Acta Endocrinologica, 85 (4), 823-831.   
         
Hoyer, D., Clarke, D.E., Fozrd, J.R., Hartig, P.R., Martin, G.R., Mylecharane, E.J.,  
       et al., (1994).  VII.  International Union of Pharmacology classification of receptors for    
       5-hydroxytryptamine (serotonin).  Pharmacological Reviews, 46 (2), 157-203. 
        
Humphrey, P.P., Hartig, P., & Hoyer, D., (1993).  A proposed new nomenclature for  
       5-HT receptors.  Trends in Pharmacological Sciences, 14 (6), 233-236. 
         
Huttunen, M., (1995).  The evolution of the serotonin-dopamine antagonist concept.   
       Journal of Clinical Psychopharmacology, 15 (1 Suppl 1), 4S-10S. 
        
Inoue, T., Koyama, T., & Yamashita, I., (1992).  From a standpoint of psychiatry:  
       effects of conditioned fear stress on monoaminergic systems in the rat brain.  Japanese  
       Journal of Clinical Pathology, 40 (3), 227-233. 
         
Islam, A., Thompson, K.S., Akhtar, S., & Handley, S.L., (2004).  Increased 5-HT2A  
       receptor expression and function following central glucocorticoid receptor knockdown    
       in vivo.  European Journal of Pharmacology, 502(3), 213-220. 
 
Izumi, T., Suzuki, K., Inoue, T., Li, X.B., Maki, Y., Muraki, I., et al., (2002).  Long- 
       lasting change in 5-HT2A receptor-mediated behavior in rats after a single footshock.   
       European Journal of Pharmacology, 452(2), 199-204. 
         
Jacobson, L., & Sapolsky, R., (1991).  The role of the hippocampus in feedback  
       regulation of the hypothalamic-pituitary-adrenocortical axis.  Endocrine Reviews, 12 (2),  
       118-134. 
         
Jorgensen, H., Knigge, U., & Warberg, J., (1992).  Effect of serotonin 5-HT1, 5- 
       5T2, and 5-HT3 receptor antagonists on the prolactin response to restraint and ether  
       stress.  Neuroendocrinology, 56 (3), 371-377. 
 
Kaur, P., & Ahlenius, S., (1997).  Potentiation of DOI-induced forward locomotion  
       in rats by (-)-pindolol pretreatment.  Journal of Neural Transmission, 104 (6-7), 605-   
       614. 







Kennett, G.A., Dourish, C.T., & Curzon, G., (1987).  Antidepressant-like action of  
       5-HT1A agonists and conventional antidepressants in an animal model of depression.   
       European Journal of Pharmacology, 134 (3), 265- 274. 
 
Kennett, G.A., Wood, M.D., Bright, F., Trail, B., Riley, G., Holland, V., et al.,  
       (1997).  SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist.   
       Neuropharmacology, 36 (4-5), 609-620. 
      
Kimura, H., et al., (1992).  Role of adrenergic neuronal activity in the yawning  
       induced by tacrine and NIK-247 in rats.  Pharmacology, Biochemistry, and Behavior, 43  
       (4), 985-991.   
         
Koch, J.E., & Bodnar, R.J., (1993).  Involvement of mu1 and mu2 opioid receptor  
       subtypes in tail-pinch feeding in rats.  Physiology and Behavior, 53 (3), 603-605. 
         
Koskinen, T., Haapalinna, A., & Sirvio, J., (2003).  Alpha-adrenoceptor-mediated  
       modulation of 5-HT2 receptor agonist induced impulsive responding in a 5-choice serial  
       reaction time task.  Pharmacology and Toxicology, 92 (5), 214-25. 
         
Koskinen, T., et al., (2000).  Activation of 5-HT2A receptors impairs response  
       control of rats in a five-choice serial reaction time task.  Neuropharmacology, 39 (3),    
       471-481. 
         
Kostowski, W., Plaznik, A., Nazar, M., & Jessa, M., (1995).  Antagonism of  
       behavioral effects of electroconvulsive shock but not those of desipramine by the  
       selective 5-HT3 receptor antagonist, ondansetron.  Polish Journal of Pharmacology, 47  
       (2), 193-195. 
         
Kostowski, W., Plaznik, A., & Stefanski, R., (1989).  Intra-hippocampal buspirone  
       in animal models of anxiety.  European Journal of Pharmacology, 168 (3), 393-396. 
         
Kostrzewa, R.M., & Kastin, A.J., (1993).  Tyr-MIF-1 attenuates development of  
       tolerance to spiperone-induced catalepsy in rats.  Brain Research Bulletin, 31 (6), 707- 
       712. 
         
Krebs-Thompson, K., Paulus, M.P., & Geyer, M.A., (1998).  Effects of  
       hallucinogens on locomotor and investigatory activity and patterns: influence of 5-HT2A  
       and 5-HT2C receptors.  Neuropsychopharmacology, 18 (5), 339-351. 
         
Kudsk, K.A., & Mirtallo, J.M., (1983).  Nutritional support of the critically ill  










Kulikov, A., Aguerre, S., Berton, O., Ramos, A., Mormede, P., & Chaouloff, F.,  
       (1997).  Central serotonergic systems in the spontaneously hypertensive and Lewis rat  
       strains that differ in the elevated plus-maze test of anxiety.  Journal of Pharmacology and  
       Experimental Therapeutics, 281(2), 775-84.  
         
Kurashima, M., et al., (1996).  Inhibitory effects of putative dopamine D3 receptor  
       agonists, 7-OH-DPAT and quinpirole, on prolactin secretion in rats.  Pharmacology,  
       Biochemistry, and Behavior, 53 (2), 379-383.   
         
Kurashima, M., Yamada, K., Nagashima, M., Shirakawa, K., & Furukawa, T.,  
       (1995).  Effects of putative dopamine D3 receptor agonists, 7-OH-DPAT, and   
       quinpirole, on yawning, stereotypy, and body temperature in rats.  Pharmacology,  
       Biochemistry, and Behavior, 52 (3), 503-508. 
        
Levine, A.S., & Morley, J.E., (1981).  Stress-induced eating in rats.  American Journal  
       of Physiology, 241 (1), R72-6. 
         
McBlane, J.W., & Handley, S.L., (1994).  Effects of two stressors on behaviour in  
       the elevated X-maze: preliminary investigation of their interaction with 8-OH-DPAT.   
       Psychopharmacology, 116 (2), 173-182. 
         
McEwen, B.S., De Kloet, E.R., & Rostene, W., (1986).  Adrenal steroid receptors  
       and actions in the nervous system.  Physiological Reviews, 66 (4), 1121-88. 
         
McEwen, B.S., & Stellar, E. (1993).  Stress and the individual. Mechanisms leading  
       to disease.  Archives of Internal Medicine, 153 (18), 2093-2101. 
         
Maes, M., Libbrecht, I., van Hunsel, F., Campens, D., & Meltzer, H.Y., (1999).  
       Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized  
       major depressed patients, including those with treatment resistance.  Journal of Clinical  
       Psychopharmacology, 19 (2), 177-182. 
         
Maisonnette, S., Villela, C., Carotti, A.P., & Landeira-Fernandez, J., (2000).  
       Microinfusion of nefazodone into the basolateral nucleus of the amygdala enhances  
       defensive behavior induced by NMDA stimulation of the inferior colliculus.  Physiology  
       & Behavior, 70 (3-4), 243-247. 
 
Makara, G.B., Stark, E., Karteszi, M., Palkovits, M., & Rappay, G., (1981).  Effects  
       of paraventricular lesions on stimulated ACTH release and CRF in stalk-median  
       eminence of the rat.  American Journal of Physiology, 240 (4), E441-E446.    
        
Malone, H.M., Peters, J.A., & Lambert, J.J., (1991).  Physiological and  
       pharmacological properties of 5-HT3 receptors--a patch clamp-study.  Neuropeptides,     







Marcinkiewicz, M., Verge, D., Gozlan, H., Pichat, L., & Hamon, M., (1984).  
       Autoradiographic evidence for the heterogeneity of 5-HT1 sites in the rat brain.  Brain  
       Research, 291 (1), 159-163. 
         
Marek, G.J., (2003).  Behavioral evidence for mu-opioid and 5-HT2A receptor  
       interactions.  European Journal of Pharmacology, 474(1), 77-83. 
         
Maslova, L.N., Bulygina, V.V., & Markel, A.L., (2002).  Chronic stress during  
       prepubertal development: immediate and long-lasting effects on arterial blood pressure     
       and anxiety-related behavior.  Psychoneuroendocrinology, 27 (5), 549-561. 
          
Matsumoto, S., Yamada, K., Nagashima, M., Domae, M., Shirakawa, K., &  
       Furukawa, T., (1989).  Occurrence of yawning and decrease of prolactin levels via  
       stimulation of dopamine D2-receptors after administration of SND 919 in rats.  Naunyn-  
       Schmiedebergs Archives of Pharmacology, 340 (1), 21-25. 
         
Matsumoto, S., Yamada, K., Nagashima, M., Matsuo, N., Shirakawa, K., &  
       Furukawa, T., (1989).  Potentiation by serotonergic inhibition of yawning induced by  
       dopamine receptor agonists in rats.  Pharmacology, Biochemistry, and Behavior, 32 (3),  
       815-818.  
         
Middlemiss, D.N., Bremer, M.E., & Smith, S.M., (1988).  A pharmacological  
       analysis of the 5-HT receptor mediating inhibition of 5-HT release in the guinea-pig  
       frontal cortex.  European Journal of Pharmacology, 157 (1), 101-107. 
         
Mitchell, P.J., Fairhall, S.J., Fletcher, A., & Redfern, P.H., (2003).  Effects of single and  
       repeated electroconvulsive shock on the social and agonistic behaviour of resident rats.   
       Neuropharmacology, 44(7), 911-925.   
         
Mizoguchi, K., Yuzurihara, M., Ishige, A., Sasaki, H., Chui, D.H., Tabira, T.,  
       (2001).  Chronic stress differentially regulates glucocorticoid negative feedback response  
       in rats.  Psychoneuroendocrinology, 26 (5), 443-459. 
         
Mora, P.O., Netto, C.F., & Graeff, F.G., (1997).  Role of 5-HT2A and 5-HT2C  
       receptor subtypes in the two types of fear generated by the elevated T-maze.   
       Pharmacology, Biochemistry, and Behavior, 58 (4), 1051-1057. 
         
Motta, V., Maisonnette, S., Morato, S., Castrechini, P., & Brandao, M.L., (1992).  
       Effects of blockade of 5-HT2 receptors and activation of 5-HT1A receptors on the    
       exploratory activity of rats in the elevated plus-maze.  Psychopharmacology (Berlin),   
       107 (1), 135-9. 
 
Munck, A., Guyre, P.M., & Holbrook, N.J. (1984).  Physiological functions of  
       glucocorticoids in stress and their relation to pharmacological actions.  Endocrine  






Nic Dhonnchadha, B.A., Hascoet, M., Jolliet, P., & Bourin, M., (2003).  Evidence for a  
       5-HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice.   
       Behavioral Brain Research, 147 (1-2), 175-184. 
 
Nonaka, K.O., (1999).  Involvement of 5-HT3 receptors in the prolactin release  
       induced by immobilization stress in rats.  Progress in Neuro-psychopharmacology &  
       Biological Psychiatry, 23 (3), 497-503. 
        
Olivier, B., Pattij, T., Wood, S.J., Oosting, R., Sarnyai, Z., & Toth, M., (2001).  The  
       5-HT1A receptor knockout mouse and anxiety.  Behavioural Pharmacology, 12 (6-7),  
       439-450. 
         
Olivier, B., Molewijk, H.E., van der Heyden, J.A., van Oorschot, R., Ronken, E., Mos,  
       J., et al., (1998).  Ultrasonic vocalizations in rat pups: effects of serotonergic ligands.   
       Neuroscience and Biobehavioral Reviews, 23 (2), 215-217. 
         
Osborn, J.A., Yu, C., Gabriel, K., & Weinberg, J., (1998).  Fetal ethanol effects on  
       benzodiazepine sensitivity measured by behavior on the elevated plus-maze.     
       Pharmacology, Biochemistry, and Behavior, 60(3), 625-33. 
         
Ossowska, K, Smialowska, M, & Wolfarth, S., (1982).  A biphasic influence of  
       globus pallidus lesions: spontaneous catalepsy followed by anticataleptic effect.   
       Pharmacology, Biochemistry, and Behavior, 19 (2), 169-176. 
         
Ouagazzal, A., Grottick, A.J., Moreau, J., & Higgins, G.A., (2001).  Effect of LSD  
       on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis  
       and comparison between two rat strains.  Neuropsychopharmacology, 25 (4), 565-575. 
        
Pacak, K., Palkovits, M., Kopin, I.J., & Goldstein, D.S., (1995).  Stress-induced  
       norepinephrine release in the hypothalamic paraventricular nucleus and pituitary- 
       adrenocortical and sympathoadrenal activity: in vivo microdialysis studies.  Frontiers in  
       Neuroendocrinology, 16 (2), 89-150. 
    
Plotsky, P.M., (1987).  Facilitation of immunoreactive corticotropin-releasing factor  
       secretion into the hypophysial-portal circulation after activation of catecholaminergic  
       pathways or central norepinephrine injection.  Endocrinology, 121 (3), 924-930. 
         
Rademacher, D.J., Anderson, A.P., & Steinpreis, R.E., (2002).  Acute effects of  
       amperozide and paroxetine on social cohesion in male conspecifics.  Brain Research  
       Bulletin, 58 (2), 187-191. 
         
Radja, F., Laporte, A.M., Daval, G., Verge, D., Golan, H., & Hamon, M., (1991).   
       Autoradiography of serotonin receptor subtypes in the central nervous system.   
       Neurochemistry International, 18, 1-15. 






Radulovic, J., Ruhmann, A., Liepold, T., & Spiess, J., (1999).  Modulation of learning  
       and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF  
       receptors 1 and 2.  Journal of Neuroscience, 19 (12), 5016-5025. 
         
Raghavendra, V., & Kulkarni, S.K., (2000).  Melatonin reversal of DOI-induced  
       hypophagia in rats; possible mechanism by suppressing 5-HT2A receptor-mediated  
       activation of HPA axis.  Brain Research, 860 (1-2), 112-118. 
         
Rapport, M.M., Green, A.A., & Page, I.H., (1944).  Serum vasoconstrictor  
       (serotonin).  IV.  Isolation and characterization.  Journal of Biology and Chemistry, 176,  
       1243-1251. 
        
Rebuffe-Scrive, M., Walsh, U.A., McEwen, B., & Rodin, J., (1992).  Effect of  
       chronic stress and exogenous glucocorticoids on regional fat distribution and  
       metabolism.  Physiology & Behavior, 52 (3), 583-590. 
         
Rittenhouse, P.A., Bakkum, E.A., Van de Kar, L.D., (1994).  Evidence that ACTH  
       secretion is regulated by serotonin 2A/2C (5-HT2A/2C) receptors.  Journal of  
       Pharmacological and Experimental Therapeutics, 271 (3), 1647-1655. 
         
Rittenhouse, P.A., Bakkum, E.A., & Van de Kar, L.D., (1991).  Evidence that the  
       serotonin agonist, DOI, increases renin secretion and blood pressure through both  
       central and peripheral 5-HT2 receptors.  Journal of Pharmacological and Experimental  
       Therapeutics, 259 (1), 58-65. 
         
Rogers, D.C., Costall, B., Domeney, A.M., Gerrard, P.A., Greener, M., Kelly, M.E., et  
       al., (2000).  Anxiolytic profile of ropinirole in the rat, mouse and common marmoset.   
       Psychopharmacology (Berlin), 151 (1), 91-7. 
         
Rowan, M.J., Cullen, W.K., & Moulton, B., (1990).  Buspirone impairment of  
       performance of passive avoidance and spatial learning tasks in the rat.   
       Psychopharmacology, 100 (3), 393-398. 
         
Samarghandian, S., Ohata, H., Yamauchi, N., & Shibasaki, T., (2003).  Corticotropin- 
       releasing factor as well as opioid and dopamine are involved in tail-pinch-induced food  
       intake of rats.  Neuroscience, 116 (2), 519-524. 
         
Sanchez, C., Gruca, P., Bien, E. and Papp, M., (2003).  R-citalopram counteracts the  
       effect of escitalopram in a rat conditioned fear stress model of anxiety.  Pharmacology,  
       Biochemistry, and Behavior, 75 (4), 903-907.  
         
Saphier, D., & Feldman, S., (1989).  Adrenoceptor specificity in the central  
       regulation of adrenocortical secretion.  Neuropharmacology, 28 (11), 1231-1237. 







Saphier, D., & Feldman, S., (1991).  Catecholaminergic projections to  
       tuberoinfundibular neurones of the paraventricular nucleus: III. Effects of adrenoceptor  
       agonists and antagonists.  Brain Research Bulletin.  26 (6), 863-870. 
         
Schreiber, R., Melon, C., & De Vry, J., (1998).  The role of 5-HT receptor subtypes  
       in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic  
       vocalization test.  Psychopharmacology, 135 (4), 383-391. 
         
Schreiber, R., Opitz, K., Glaser, T., & De Vry, J., (1993).  Ipsapirone and 8-OH- 
       DPAT reduce ethanol preference in rats: involvement of presynaptic 5-HT1A receptors.   
       Psychopharmacology, 112 (1), 100-110. 
         
Selye, H., (1956).  The stress of life.  New York: McGraw-Hill. 
 
Simmons, P.S., Miles, J.M., Gerich, J.E., & Haymond, M.W., (1984).  Increased  
       proteolysis. An effect of increases in plasma cortisol within the physiologic range.   
       Journal of Clinical Investigation, 73 (2), 412-420. 
         
Setem, J., Pinheiro, A.P., Motta, V.A., Morato, S., & Cruz, A.P., (1999).   
       Ethopharmacological analysis of 5-HT ligands on the rat elevated plus-maze.    
       Pharmacology, Biochemistry, and Behavior, 62 (3), 515-521. 
         
Singh, Y., Jaiswal, A.K., Singh, M., & Bhattacharya, S.K., (1998).  Effect of prenatal  
       diazepam, phenobarbital, haloperidol and fluoxetine exposure on foot shock induced  
       aggression in rats.  Indian Journal of Experimental Biology, 36 (10), 1023-4. 
         
Sobrian, S.K., Jones, B.L., Varghese, S., & Holson, R.R., (2003).  Behavioral  
       response profiles following drug challenge with dopamine receptor subtype agonists and  
       antagonists in developing rat.  Neurotoxicology and Teratology, 25 (3), 311-328. 
         
Stefanski, R., Paleijko, W., Bidzinski, A., Kostowski, W., & Plaznik, A., (1993).  
       Serotonergic innervation of the hippocampus and nucleus accumbens septi and the  
       anxiolytic-like action of the 5-HT3 receptor antagonists.  Neuropharmacology, 32 (10),  
       987-993. 
         
Stefanski, R., Paleijko, W., Kostowski, W., & Plaznik, A., (1992).  The comparison  
       of benzodiazepine derivatives and serotonergic agonists and antagonists in two animal  
       models of anxiety.  Neuropharmacology, 31 (12), 1251-1258. 
         
Stutzmann, J.M., Eon, B., Darche, F., Lucas, M., Rataud, J., Piot, O., et al., (1991).   
       Are 5-HT2 antagonists endowed with anxiolytic properties in rodents?  Neuroscience  
       Letters, 128 (1), 4-8. 








Szafarczyk, A., Malaval, F., Laurent, A., Gibaud, R., & Assenmacher, I, (1987).  
       Further evidence for a central stimulatory action of catecholamines on  
       adrenocorticotropin release in the rat.  Endocrinology, 121 (3), 883-892. 
         
Szechtman, H., & Hall, W.G., (1980).  Ontogeny of oral behavior induced by tail pinch  
       and electrical stimulation of the tail in rats.  Journal of Comparative Physiology and  
       Psychology, 94 (3), 436-45. 
         
Tarchalska-Krynska, B., & Kowstowski, W., (1976). Effects of drugs influencing  
       serotonergic mechanisms on behaviour of insects.  Polish Journal of Pharmacology and  
       Pharmacy, 28 (6), 635-639. 
         
To, C.T., & Bagdy, G., (1999).  Anxiogenic effect of central CCK administration is  
       attenuated by chronic fluoxetine or ipsapirone treatment.  Neuropharmacology, 38(2),    
       279-82. 
         
Udelsman, R., & Holbrook, N.J., (1994).  Endocrine and molecular responses to  
       surgical stress.  Current Problems in Surgery, 31 (8), 653-720. 
         
Van de Kar, L.D., & Blair, M.L., (1999).  Forebrain pathways mediating stress- 
       induced hormone secretion.  Frontiers in Neuroendocrinology, 20 (1), 1-48. 
         
Varty, G.B., Bakshi, V.P., & Geyer, M.A., (1999).  M100907, a serotonin 5-HT2A  
       receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse  
       inhibition deficits in Sprague-Dawley and Wistar rats.  Neuropsychopharmacology, 20  
       (4), 311-321.   
        
Vasar, E., Peuranen, E., Oopik, T., Harro, J., & Mannisto, P.T., (1993).   
       Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect  
       of caerulein, an agonist of CCK receptors, in the elevated plus-maze.   
       Psychopharmacology, 110 (1-2), 213-218. 
         
Venter, J.C., Di Porzio, U., Robinson, D. A., Shreeve, S.M., Lai, J., Kerlavage,  
       et.al., (1988).  Evolution of the neurotransmitter receptor systems.  Progress in  
       Neurobiology, 30, 105-169. 
 
Welch, J.E., Farrar, G.E., Dunn, A.J., & Saphier, D., (1993).  Central 5-HT1A  
       receptors inhibit adrenocortical secretion.  Neuroendocrinology, 57 (2), 272-281. 
         
Wettstein, J.G., Host, M., & Hitchcock, J.M., (1999).  Selectivity of action of typical  
       and atypical anti-psychotic drugs as antagonists of the behavioral effects of 1-[2,5- 
       dimethoxy-4-iodophenyl]-2-aminopropane (DOI).  Neuropsychopharmacology and  








Whitton, P.S., Sarna, G.S., Datla, K.P., & Curzon, G., (1991).  Effects of tianeptine on  
       stress-induced behavioural deficits and 5-HT dependent behaviour.   
       Psychopharmacology (Berlin), 104 (1), 81-5. 
 
Wilander, E., Lundqvist, M., & Oberg, K., (1989).  Gastrointestinal carcinoid  
       tumours. Histogenetic, histochemical, immunohistochemical, clinical and therapeutic  
       aspects.  Progress in Histochemistry and Cytochemistry, 19 (2), 1-88. 
      
Willins, D.L., & Meltzer, H.Y., (1997).  Direct injection of 5-HT2A receptor  
       agonists into the medial prefrontal cortex produces a head-twitch response in rats.   
       Journal of Pharmacology and Experimental Therapeutics, 282 (2), 699-706. 
 
Yamada, K., et al., (1986).  Effects of new neuroleptics, isofloxythepin and zotepine,  
       on post-decapitation convulsions and prolactin secretion in rats.  Pharmacology,  





































       Vita 
 
       John Hearn is a native of Ruston, Louisiana.  He received a Bachelor of Science degree  
 
in psychology from Louisiana State University in 2002.  Currently, he is a graduate student in  
 
the doctoral program of the Department of Psychology at Louisiana State University, and  
 
will earn his master’s degree in May, 2005. 
   










         
 
  
   
         
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
